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Sommario 
L’immunosenescenza e l’invecchiamento prematuro rappresentano importanti fattori di 
rischio per l’insorgenza di tumore; il deterioramento delle funzioni immunitarie e 
l’accumulo di danni al DNA con l’avanzare dell’età determinano un generale 
peggioramento dello stato di salute e predispongono alla malattia neoplastica. Come 
risultato della maggiore aspettativa di vita, è previsto che il numero di tumori nella 
popolazione anziana aumenterà significativamente nei prossimi anni. E’ sempre più 
importante, pertanto, trovare dei marcatori prognostici per l’insorgenza di cancro e/o di 
risposta alla terapia, anche al fine di migliorare il trattamento di questa popolazione più 
vulnerabile. Va inoltre sottolineato che certe condizioni, come l’infezione da HIV, 
sembrano accelerare il processo di invecchiamento e di immunosenescenza; l’attivazione 
cronica del sistema immunitario potrebbe giocare un ruolo critico in queste disfunzioni, 
che, oltre all’immunodepressione, potrebbero costituire un importante fattore di rischio 
per l’insorgenza dei tumori associati ad HIV. L’alta incidenza di tumore fra gli individui 
HIV-infetti, rispetto alla popolazione generale di pari età, anche dopo l’introduzione della 
terapia antiretrovirale (ART) che riduce i livelli di HIV e parzialmente ripristina il 
sistema immunitario, va a sostegno dell’ipotesi che altre condizioni, oltre 
all’immunodepressione, possano giocare un ruolo nel processo di cancerogenesi nelle 
persone HIV-infette. Questo è di particolare rilievo nei bambini con infezione perinatale 
da HIV, nei quali il sistema immunitario co-evolve dalla nascita con il virus. Dopo 
l’introduzione dell’ART, la maggior parte dei bambini HIV-infetti diventa adolescente ed 
entra nell’età adulta; nonostante la terapia, questi rimangono ad alto rischio di tumore. 
Il mio progetto di Dottorato si è focalizzato sullo studio dell’immunosenescenza e 
dell’invecchiamento prematuro in due popolazioni ad alto rischio di cancro: i soggetti 
anziani e i bambini con infezione perinatale da HIV. 
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1. Immunosenescenza e cancro negli anziani 
In questo studio sono stati analizzati l’output timico, il profilo immunofenotipico dei 
linfociti CD4
+
 e CD8
+
 e la lunghezza del telomero (TL) nel sangue periferico di pazienti 
con cancro di età superiore ai 70 anni. Sono stati arruolati 52 soggetti anziani con cancro 
e 39 controlli di pari età senza storia di cancro. Le percentuali di cellule C8
+
 naive e CD8
+
 
di recente uscita timica e i livelli di TREC (“T-cell receptor excision circles”, marker 
molecolare per valutare l’output timico) erano significativamente più bassi nei pazienti 
con cancro che nei controlli (16.7% [9.3-25.2] vs 24.6% [14.7-33.5], p=0.003; 34.2% 
[24.7-46.4] vs 44.9% [36.0-50.7], p=0.004; 16.0 [7.7-31.5] vs 25.0 [14.0-56.0] TREC 
copies/10
5
 PBMC, p=0.031; rispettivamente). La TL nelle cellule mononucleari di sangue 
periferico (PBMC) era significativamente più corta nei pazienti con cancro che nei 
controlli (p=0.046) e correlava con l’età solo in quest’ultimi (r=-0.354, p=0.031). Il 
profilo telomeri corti(≤mediana)/bassi livelli di TREC (≤mediana) era associato con un 
alto rischio di cancro (OR=3.68 [95%CI 1.22-11.11]; p=0.021). E’ in corso un sottostudio 
longitudinale al fine di valutare l’impatto di questi marcatori sulla risposta alla 
chemioterapia e/o sul decorso della malattia. Dati preliminari hanno mostrato, che dopo il 
trattamento chemioterapico, vi è un aumento delle cellule CD8
+
 differenziate allo stadio 
terminale (p=0.031), e che l’accorciamento del telomero durante il follow-up tende ad 
essere maggiore nei pazienti con malattia di stadio III rispetto a quelli di stadio II. Inoltre, 
l’analisi del danno al DNA nei PBMC, prima e dopo l’esposizione ad una sorgente di 
raggi gamma, ha suggerito che i pazienti con cancro hanno una ridotta efficienza nei 
processi di riparo del DNA. In generale, questi risultati indicano che l’immunosenescenza 
è significativamente più grave nei pazienti anziani con cancro rispetto ai controlli di pari 
età. Il basso output timico e i telomeri più corti nelle cellule di sangue periferico 
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potrebbero riflettere una condizione pre-esistente, che facilita l’insorgenza di tumore nelle 
persone anziane e che potrebbe influenzare la risposta alla chemioterapia. 
 
2. Invecchiamento prematuro nei bambini con infezione perinatale da HIV 
Sono stati studiati 71 bambini HIV-infetti (HIV+) nati da madre HIV-infetta, dai 0 ai 5 
anni di età, 65 bambini esposti non infetti (HEU) nati da madre HIV-infetta e 56 non 
esposti non infetti (HUU) di pari età. Il 42% dei bambini HIV+ non era in ART. La TL 
era significativamente più corta nei bambini HIV+ rispetto ai bambini HEU e HUU 
(p<0.0001, dopo aggiustamento per età); inoltre, i bambini HIV+ ART-naive mostravano 
una TL più corta rispetto ai bambini in ART (mediana 2.11 [range interquartilico (IQR) 
1.75-2.37 vs 2.46 [2.07-2.68]; p=0.0029, dopo aggiustamento per età). Le cellule CD8
+
 di 
recente uscita timica (CD45RA
+
CD31
+
) e i livelli di TREC erano significativamente più 
bassi nei bambini HIV+ rispetto ai bambini HEU e HUU (p=0.005 e p=0.0249, 
rispettivamente), mentre le percentuali delle cellule CD8
+
 di memoria effettrici 
(CD45RA
-
CD27
-
) e differenziate allo stadio terminale (CD45RA
+
CD27
-
) erano maggiori 
nei primi (p=0.033 e p<0.001, rispettivamente). Le cellule CD8
+
 senescenti (CD28
-
CD57
+
) erano maggiori negli HIV+ che nei bambini HEU e HUU (25.8% [12.4-43.2] vs 
8.5% [6.8-16.7] vs 9.7% [3.3-27.3]; p=0.004), così come le cellule CD8
+
 attivate 
(CD38
+
HLA-DR
+
) (7.0% [5.2-12.2] vs 3.5% [3.9-7.6] vs 3.7 [2.4-6.7]; p<0.001) e le 
cellule CD8
+
PD-1
+
 (7.1% [5.0-12.4] vs 3.5% [2.1-5.9] vs 3.7% [2.4-5.3]; p<0.001). 
All’interno della sottopopolazione di cellule CD4+, la percentuale delle cellule senescenti 
non era significativamente diversa fra HIV+ e controlli, sebbene l’espressione di PD-1 
tendesse ad essere maggiore negli HIV+ (p=0.050). Nell’insieme, questi dati 
suggeriscono che i bambini HIV-infetti mostrano un invecchiamento prematuro e uno 
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stato di immunosenescenza accelerato che colpisce per lo più la sottopopolazione delle 
cellule CD8
+. L’infezione da HIV per sé sembra influenzare il processo di 
invecchiamento, piuttosto che l’esposizione all’ART per profilassi o trattamento. I 
meccanismi attraverso i quali HIV potrebbe influenzare queste funzioni rimangono 
ancora da chiarire; comunque, l’attivazione cronica del sistema immunitario dovuta alla 
persistenza degli antigeni virali potrebbe promuovere la rapida proliferazione delle cellule 
CD8
+
 causando l’erosione dei telomeri e determinando il fenotipo immunosenescente. 
Conclusioni 
Nel complesso questi studi suggeriscono che la lunghezza dei telomeri, l’output timico e 
l’analisi immunofenotipica rappresentano dei marcatori utili per monitorare 
l’invecchiamento prematuro e l’immunosenescenza. Nei pazienti anziani, il basso output 
timico e i telomeri corti sono significativamente associati al tumore e potrebbero 
influenzare la risposta alla chemioterapia. Pertanto, questi marcatori potrebbero essere 
utili nella popolazione anziana per predire l’insorgenza di neoplasia e pianificare strategie 
terapeutiche. Nel contesto dell’infezione pediatrica da HIV, il nostro studio indica 
l’importanza di analizzare, in aggiunta agli esami correnti, come la plasmaviremia HIV e 
il profilo delle cellule CD4
+
, la lunghezza del telomero e le sottopopolazioni delle cellule 
CD8
+
, al fine di valutare lo stato di invecchiamento prematuro e l’immunosenescenza in 
questa popolazione ad alto rischio di cancro. 
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Summary 
Immune senescence and premature aging are important tumor risk factors. Decline in 
immune functions and accumulation of DNA damages influence overall health and 
predispose to malignancies. As a result of longer life expectancy, the number of cancers 
in the elderly population is expected to increase significantly over the next years. 
Considering the effect of the growing geriatric population on cancer care, the need to 
develop prognostic markers for cancer onset and/or chemotherapy response for improved 
treatment in this frail population is becoming greater. Furthermore, several conditions, 
such as HIV infection, also appear to accelerate aging and immune senescence; chronic 
immune activation may play a critical role in these dysfunctions which, besides immune 
depression, may constitute important risk factors for the onset of HIV-associated tumors. 
The persistence of a higher incidence of malignancies in HIV-infected individuals 
compared with the age-matched general population, even after the introduction of 
antiretroviral therapy (ART), which can reduce HIV levels and partially restore the 
immune functions, indicates that other conditions than immune depression play a role in 
the cancerogenesis occurring in HIV-infected patients. This is of particular importance in 
the perinatally HIV-infected children in whom the immune system co-evolves with HIV 
from birth. After the introduction of ART, most perinatally HIV-infected children are 
entering into adolescence and young adulthood and, despite ART, they remain at high 
risk of malignancies.  
My PhD project focuses on the study of immune senescence and premature aging in two 
populations at higher risk of cancer: elderly people and perinatally HIV-infected children. 
 
 
 
10 
 
1. Immune senescence and cancer in elderly people 
This study analyzed thymic output, immunophenotypic profile of CD4
+
 and CD8
+
 
lymphocytes and peripheral blood telomere length (TL) in cancer patients 70≥ years old. 
Fifty-two elderly cancer patients and 39 age-matched controls without personal history of 
cancer were enrolled. The percentages of CD8
+
 naïve and CD8
+
 recent thymic emigrant 
cells (RTE) cells and levels of TREC (T-cell receptor excision circles, a molecular marker 
to evaluate thymic output) were significantly lower in cancer patients than in controls 
(16.7% [9.3-25.2] vs 24.6% [14.7-33.5], p=0.003; 34.2% [24.7-46.4] vs 44.9% [36.0-
50.7], p=0.004; 16.0 [7.7-31.5] vs 25.0 [14.0-56.0] TREC copies/10
5
 PBMC, p=0.031; 
respectively). TLs in peripheral blood mononuclear cells (PBMC) were significantly 
shorter in cancer patients than they did in controls (p=0.046) and did not correlate with 
age in patients, whereas it did in controls (r=-0.354, p=0.031). Short 
telomere(≤median)/low TREC(≤median) profile was associated with a higher risk of 
cancer (OR=3.68 [95%CI 1.22-11.11]; p=0.021). A longitudinal substudy is in progress 
to evaluate the effect of these markers on chemotherapy response and/or disease outcome. 
Preliminary data from this longitudinal substudy showed that, after chemotherapy 
treatment, there was an increase in CD8
+
 terminally differentiated cells (p=0.031), and 
telomere shortening at follow-up tended to be greater in stage III patients than in those at 
stage II. In addition, analysis of DNA-damage in PBMC, before and after exposure to a 
source of y-radiation, suggested that the DNA repair process is less efficient in cancer 
patients than in controls. Taken together, these findings indicate that immune senescence 
is significantly worse in elderly cancer patients than in age-matched controls. The low 
thymic output and the short telomeres in peripheral blood cells of cancer patients may 
reflect a pre-existing condition which facilitates the onset of malignancies in elderly 
people and may affect the response to chemotherapy and disease outcome. 
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2. Premature aging in perinatally HIV-infected children 
Seventy-one HIV-infected (HIV+) children born to HIV-infected mothers, aged from 0-5 
years, 65 HIV-exposed-uninfected (HEU) born to HIV-infected mothers and 56 HIV-
unexposed-uninfected (HUU) age-matched children were studied. 42% of the HIV+ 
children were not on ART. TLs were significantly shorter in HIV+ than in HEU and 
HUU children (overall p<0.0001, adjusted for age); in addition, HIV+ ART-naïve 
children had shorter TLs than children on ART (median 2.11 [interquartile range (IQR) 
1.75-2.37] vs 2.46 [2.07-2.68]; p=0.0029 adjusted for age). CD8
+
 RTE (CD45RA
+
CD31
+
) 
and TREC levels were significantly lower in the HIV+ group than in the HEU and HUU 
groups (overall, p=0.005 and p=0.0249, respectively), whereas percentages of CD8
+
 
effector memory (CD45RA-CD27-) and terminally differentiated cells (CD45RA
+
CD27
-
) 
were higher in the former (overall, p=0.033, and p<0.001, respectively). CD8
+
 senescent 
cells (CD28
-
CD57
+
) were higher in HIV+ than in HEU and HUU children (25.8% [12.4-
43.2] vs 8.5% [6.8-16.7] vs 9.7% [3.3-27.3]; p=0.004), as were CD8
+
 activated cells 
(CD38
+
HLA-DR
+
) (7.0% [5.2-12.2] vs 3.5% [3.9-7.6] vs 3.7% [2.4-6.7]; p<0.001) and 
CD8
+
PD-1
+
 cells (7.1% [5.0-12.4] vs 3.5% [2.1-5.9] vs 3.7% [2.4-5.3]; p<0.001). Within 
the CD4
+
 cell subset, percentages of senescent cells did not differ between HIV+ and 
controls, although PD-1 expression tended to be up-regulated in HIV+ children (overall, 
p=0.050). Overall, these data suggest that HIV-infected children exhibit premature aging 
and accelerated immune senescence, which particularly affects the CD8
+
 cell subset. HIV 
infection per se seems to influence the aging process, rather than exposure to ART for 
prophylaxis or treatment. The mechanism(s) by means of which HIV may affect these 
functions remain to be investigated; however, chronic immune activation due to viral 
antigen persistence may promote rapid proliferation of CD8
+
 cells, resulting in erosion of 
telomeres and immunosenescent phenotype.  
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Conclusions 
Taken together these studies indicate that TL, TREC and immunophenotypic analysis are 
useful markers in monitoring premature aging and immune senescence. In elderly 
patients, low thymic output and short telomeres are significantly associated with tumor 
and may affect the response to chemotherapy. Thus, these markers may be useful in the 
elderly population to predict tumor onset and to plan therapeutic strategies. In the context 
of pediatric HIV infection, in addition to current assays, i.e. HIV plasmaviremia and 
CD4
+
 cell profile, our study indicates the need to analyze TL and CD8
+
 cell subsets to 
assess the status of premature aging and immune senescence in this population at high 
risk of cancer. 
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1. INTRODUCTION 
1.1 Aging and Cancer 
1.1.1 Aging and elderly people 
Aging represents the accumulation of changes in a person over time and coincides with a 
gradual decline in the functional reserve of multiple organ system, thus leading to 
impaired function and increased vulnerability to death. The progressive loss of 
physiological integrity that occurs with aging is the primary risk factor for major human 
chronic diseases, including cancer.  
Advances in medicine and socioeconomic development have substantially reduced 
mortality and morbidity rates due to infectious conditions and, to some extent, non-
communicable diseases. As a result of both longer life expectancy and declining fertility 
rates, the proportion of people aged over 60 years is growing faster than any other age 
group in almost every country. Between 2000 and 2050, the proportion of the world's 
population over 60 years will double from about 11% to 22% [United Nations, 2013]. The 
absolute number of people aged 60 years and over is expected to increase from 605 
million to 2 billion over the same period, and the number of people aged 80 years and 
over will have almost quadrupled between 2000 and 2050 (Figure 1). During the next 5 
years, for the first time in the world’s history, people aged 65 years and older will 
outnumber children aged younger than 5 years [United Nations, 2013].  
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Figure 1. Proportion of population aged 60 years and over between 1950-2050. [From United Nations, 
Department of Economic and Social Affairs 2013]. 
 
These demographic and epidemiological changes are accompanied by an increase of age-
associated diseases, where cardiovascular diseases and cancers (15.1%) are the leading 
contributors to disease burden in older people. In particular, the burden of malignancies in 
elderly people is forecasted to increase by 69% to 2030 [Prince MJ, Lancet 2014] (Figure 
2). 
 
Figure 2. Leading contributors to burden of disease in people aged 60 years and older [From Prince 
MJ et al, Lancet 2014]. 
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1.1.2 Biological aging and cellular senescence 
The aging process is an open question. However, the improvement of knowledge allowed 
to identify a set of distinctive characteristics of aging, and nine hallmarks have been 
recently advanced: genomic instability, telomere attrition, epigenetic alterations, 
mitochondrial dysfunction, loss of protein homeostasis, deregulated nutrient sensing, 
cellular senescence, stem cell exhaustion and altered intercellular communication [López-
Otín C et al, Cell 2013] (Figure 3). 
 
 
 
Figure 3. The hallmarks of aging. Nine common denominators of aging characterizing the mammalian 
aging: genomic instability, telomere attrition, epigenetic alterations, loss of protein homeostasis, 
deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and 
altered intercellular communication. [From López-Otín C et al, Cell 2013]. 
 
The genomic damages include point mutations, translocations, chromosomal alterations 
and gene copy number variations [Moskalev AA et al, Ageing Res Rev 2013]. These all 
can be generated by exposure to genotoxic agents and lack of efficiency of DNA repair 
mechanisms [Neri S et al, J Gerontol A Biol Sci Med Sci 2005; Engels WR et al, Cell 
Cycle 2007; St Laurent G et al, Mech Ageing Dev 2010].  
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In addition to the genetic lesions, also the epigenetic alterations (i.e. variation in DNA 
methylation or acetylation patterns) can contribute to the aging process, as these changes 
may influence chromatin remodeling and DNA stability [Fraga MF et al, Proc Natl Acad 
Sci USA 2005; Calvanese V et al, Ageing Res Rev 2009; Esteller M et al, N Engl J Med 
2008]. Despite the accumulation of DNA-damage occurs randomly in the genome, 
telomeres are the region more susceptible to age-related damage [Blasco MA, Nat Rev 
Genet 2005]. Since they are progressively shortened during each cell division, due to end-
replication problems of DNA polymerase, they represent a mitotic counter that 
determines the proliferative capacity of any normal somatic cell. Defects in telomere 
length have been implicated in the pathogenesis of several age-related diseases, including 
cancer (see section 1.1.3) [Blasco MA, Nat Rev Genet 2005]. Mitochondrial DNA 
represents another target more susceptible to injury, so that mitochondrial dysfunction has 
been hypothesized be a central mechanism driving mammalian aging [Kujoth GC et al, 
Science 2005] and capable to modulate risk of several age-associated diseases [Kenney 
MC et al, BMC Med Genet 2013; Lezi E & Swerdlow RH, Adv Exp Med Biol 2012; 
Ashar FN et al, J Mol Med 2014]. 
Cellular senescence plays a key role in the aging process. It was originally described 
more than 40 years ago as a process that limited the proliferation (growth) of human 
fibroblast after a cultivation period [Hayflick L & Moorhead PS, Exp Cell Res 1961]. 
Cellular senescence defines a condition of permanent cell-cycle arrest, in response to 
various stress beyond telomere shortening (replicative senescence), that are oncogenic 
RAS activation (oncogene-induced senescence), non-telomeric DNA-damage or 
perturbation to chromatin organization [Campisi J and d'Adda di Fagagna F, Nat Rev Mol 
Cell Biol 2007]. The cellular senescent phenotype includes a permanent arrest of cell 
proliferation, resistance to apoptosis (in some cells), and an altered pattern of genes’ 
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expression. Senescent cells accumulate in aged tissues [Dimri GP et al, Proc Natl Acad 
Sci USA 1995; Price JS et al, Aging Cell 2002; Sis B et al, Kidney Int 2007; Takayama K 
et al, J Orthop Res 2014]. 
Along with the accumulation of senescent cells, the regenerative potential of tissue is a 
distinctive marker of aging. Indeed, it has been demonstrated that, with age, the bone 
regeneration capacity [Gruber R et al, Exp Gerontol 2006] as well as T-cell 
lymphopoiesis and B-cell lymphopoiesis are compromised [Linton PJ & Dorshkind K, 
Nat Immunol 2004; Miller JP & Allman D, Semin Immunol 2005; Wang J et al, Curr 
Opin Immunol 2011]. Adult stem cells experience many stressful insults in the course of 
a lifetime of tissue repair, and thus the decrease of their function with aging may play an 
important role in the development of aging-related disease [Stenderup K et al, Bone 2003; 
Wagner W et al, PLoS One 2009; Mansilla E et al, Stem Cells Int 2011; Chakkalakal JV 
et al, Nature 2012].  
The altered intercellular communication represents another mechanism that contributes to 
the aging process and to the determination of aging phenotype. As described above, 
senescent cells acquire widespread modifications in gene expression including changes in 
cell-cycle inhibitors or activators, and also in genes encoding secreted proteins, such as 
proinflammatory cytokines and growth factors that alter the neighboring (non senescent) 
cells and the tissue microenvironment [Parrinello S et al, J Cell Sci 2005; Bavik et al C, 
Cancer Res 2006]. This phenomenon of chronic, low-grade inflammation is defined as 
“inflammaging” [Franceschi C & Campisi J, J Gerontol A Biol Sci Med Sci 2014]. 
Senescent cells display a unique phenotype, which has been termed "senescence-
associated secretory phenotype" (SASP) [Erusalimsky JD & Kurz DJ, Exp Gerontol 
2005; Acosta JC et al, Cell 2008; Coppé JP et al, PLoS One 2010; Salminen A et al, Eur J 
Neurosci 2011]. Senescent cells have been shown to disrupt normal tissue structures and 
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differentiated functions in complex cell culture models [Tsai KK et al, Cancer Res 2005], 
thus resulting in an important driver of age-related diseases [Gorenne I et al, Cardiovasc 
Res 2006; Burton DG et al, Exp Gerontol 2010; Salminen A et al, Eur J Neurosci 2011; 
Kumar M et al, Am J Respir Cell Mol Biol 2014]. 
Finally, the loss of protein homeostasis and the deregulation of nutrient sensing are 
another two common features of aging, since remarkable examples of genetic 
manipulation of the signaling pathways that regulate proteolytic system and metabolic 
system showed that these can modulate the aging process and contribute to diseases [Hipp 
MS et al, Trends Cell Biol 2014; Fontana L et al, Pro Natl Acad Sci USA 2004; Colman 
RJ et al, Nat Commun 2014]. 
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1.1.3 Cellular senescence and cancer 
The link between cell senescence and cancer has been deeply investigated to understand 
the parallel and opposite forces that drive aging and cancer. On the one hand, cancer is 
characterized by an aberrant gain of cellular fitness and aging by a loss of fitness; on the 
other hand, both cancer and aging are different manifestations of the accumulation of 
cellular damage.  
As described before, cell senescence is not simply a halt to cell proliferation, but 
coincides also with a senescent phenotype (SASP), frequently characterized by secretion 
of degradative enzymes, cytokines and growth factors that may have deleterious effect on 
function and/or homeostasis of neighboring tissues (Figure 4). 
 
 
Figure 4. Tissue damage responses and potential deleterious effect of senescent cells. [From Campisi J 
& d’Adda di Fadagna F, Nat Rev Mol Cell Biol 2007]. 
 
As briefly depicted before, the cellular proliferative span is determined by telomere 
shortening. Telomeres are the repetitive DNA sequences, bound by a complex of proteins 
(the shelterin complex) at the end of linear chromosomes [Blackburn EH et al, Nat Med 
2006], that progressively shorten at each division due to the end-replication problem in 
human somatic cells that do not express telomerase. This enzyme is a telomere-specific 
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ribonucleoprotein reverse transcriptase that adds single-stranded telomeric repeats to the 
chromosomal 3’ end, preventing telomere shortening in germ-line and in many cancer 
cells. When telomeres become critically short, they are no longer protected by the 
shelterin complex and are recognized as DNA double strand breaks [d'Adda di Fagagna F 
et al, Nature 2003]. Telomeric DNA damage causes persistent DNA-damage response 
(DDR) activation [Fumagalli M et al, Nat Cell Biol 2012], that leads to replicative 
cellular senescence and/or apoptosis [Fumagalli M et al, PLoS One 2014]. p53 and p16-
retinoblastoma (pRB) proteins are involved in the principal pathways engaged in the 
DDR response after senescent-inducing signals and also in the major tumor suppressor 
pathways. Dysfunctional telomeres, recognized as double strand breaks, activates p53, a 
crucial upstream inducer of the apoptotic pathway. Mutations that dampen the p53 or 
p16/pRB pathways cause the loss of their tumor suppressor activity, conferring resistance 
to senescence or apoptosis. Progressive shortening of telomeres increases genetic 
instability and risk of cancer [Popov N & Gil J, Epigenetics 2010; Muller PA & Vousden 
KH, Nat Cell Biol 2013]. 
Key components of the DDR, such as (Ataxia Telangiectasia Mutated) ATM, (Nijmegen 
Breakage Syndrome) NBS1 and (Checkpoint Kinase-2) CHK2, that are the first proteins 
to initiate and maintain the response to DNA-damage, drive the secretion of potent 
inflammatory cytokines, as IL-6 and IL-8, that can enforce senescence but also play a 
tumor-promoting role by favoring tumor growth, cancer cell invasiveness and 
angiogenesis [Coppé JP et al, PLoS Biol 2008; Rodier F, Nat Cell Biol 2009]. 
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1.2 Human Immunodeficiency Virus (HIV) Infection and Aging  
1.2.1 Pediatric HIV Infection 
Today, approximately 35 million people are living with HIV worldwide; more than three 
million are children [UNAIDS, Global Report 2013]. The number of new infections in 
children has decreased in the last years [UNAIDS, 2013 progress report], due to increased 
access to antiretroviral treatment (ART) to prevent mother-to-child transmission (MTCT). 
However, 240000 new pediatric HIV infections still occurred worldwide in 2013, because 
treatment coverage remains suboptimal in many countries [WHO, UNAIDS, UNICEF 
2013] (Table 1).  
Table 1. Global summary of the AIDS epidemic in 2013  
Number of people 
living with HIV in 
2013 
Total 35.0 [33.1-37.2] million 
Adults 31.8 [30.1-33.7] million 
 
Children (<15 years) 3.2 [2.9-3.5] million 
     
   People newly 
infected with HIV  
in 2013 
Total 2.1 [1.9-2.4] million 
Adults 1.9 [1.7-2.1] million 
 Children (<15 years) 240000 [210000-280000] 
      
   AIDS deaths in 2013  
Total 1.5 [1.4-1.7] million 
Adults 1.3 [1.2-1.5] million 
 
Children (<15 years) 190000 [210000-280000] 
 
[From WHO, UNAIDS, UNICEF 2013] 
 
MTCT is the main source of pediatric HIV-infection and, without prevention of MTCT, 
the overall risk of transmission is up to 40%. Most of MTCT occurs around the time of 
delivery, but it may occur also in utero; breastfeeding is an additional mode of MTCT 
[The Working Group on MTCT of HIV, J Acquir Immune Defic Syndr Hum Retrovirol 
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1995]. MTCT is a multifactorial event in which high maternal plasma HIV RNA level 
represents the major risk factor; mode of delivery and gestational age are also important 
factors [The European Collaborative Study, AIDS 1999]. Moreover, a body of evidence 
has established that also host genetic factors are important determinants of MTCT and 
HIV infection outcome [Ometto L et al, J Infect Dis 2001; Ricci E et al, J Acquir Immune 
Defic Syndr 2009; Ricci E et al, J Transl Med 2010; Freguja R et al, New Microbiol 
2012; Gianesin K et al, PLoS One 2012]. 
The course of disease progression in infants markedly differs from that in adults. The 
median time to AIDS and death in ART-untreated adults is approximately 10 years from 
infection, but in children the course of infection is faster [Collaborative Group on AIDS 
Incubation and HIV Survival, Lancet 2000; Blanche S et al, New Engl J Med 1994; 
Barnhart HX et al, Pediatrics 1996] (Figure 5). In ART-untreated children, progression of 
HIV infection follows two patterns: about 15-20% develop rapid progression to AIDS, 
whereas the others progress more slowly [Blanche S et al, Am J Dis Child 1990]. In a 
recent meta-analysis conducted in 12112 infants born from HIV-infected mothers, it was 
estimated that survival from acquisition of infection postnatally in breast-feeding children 
was higher than in those with infection acquired around delivery: 1-year mortality was 
26% among children infected through breast milk compared to 52% for peri-partum 
infected children [Becquet R et al, PLoS One 2012]. Furthermore, in a study that 
distinguished in utero, intrapartum and postnatal infections, it was estimated that median 
time from infection to death was 208, 380, and >500 days, respectively [Marinda E et al, 
Pediatr Infect Dis J 2007]. These differences in survival time are partly due to the 
immunological immaturity at the time of infection [Chakraborty R, Curr HIV Res 2005].  
The levels of plasma HIV RNA are generally higher in vertically infected children than in 
adults, persist at high levels and decline slowly with age [De Rossi A et al, J Clin Invest 
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1996; McIntosh K et al, Pediatr Infect Dis J 1996] (Figure 5). Conversely to adults, the 
relationship between CD4
+
 cell count and plasma HIV RNA is quite complex in children. 
High levels of plasmaviremia may be observed despite normal CD4
+
 lymphocyte counts, 
since CD4
+
 cell counts physiologically fall with age and plasma HIV RNA declines non-
linearly up to 5 years of life [Mofenson LM et al, J Infect Dis 1997; PENTA, AIDS 
1998].  
 
 
 
Figure 5. Dynamics of HIV RNA and CD4
+
 levels in adults and children. Relative levels of HIV RNA 
(red) and CD4
+
 cells (blue) in adults (dotted lines) and children (solid lines) in the years following 
acquisition of HIV. Gray boxes highlight the median time to AIDS/Death for infants by region and route of 
infection in comparison to adults. (US: United States). [From Tobin NH & Aldrovandi GM, Immunol Rev 
2013]. 
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1.2.2 Pediatric HIV infection and antiretroviral therapy 
The introduction of the ART has changed the natural history of pediatric HIV-1 infection, 
reducing the rate of MTCT of HIV to less than 2% [Cooper ER et al, J Acquir Immune 
Defic Syndr 2002] and resulting in a substantial decline in mortality rates and in an 
improved quality of life in HIV-infected children [Gibb DM et al, BMJ 2003; Judd A et 
al, Clin Infect Dis 2007]. ART has transformed pediatric HIV infection into a chronic 
disease and now infected infants and children often survive to adolescence and adulthood 
[Deeks SG et al, Lancet 2013; de Martino M et al, JAMA 2000; Chiappini E et al, AIDS 
2007]. Early ART leads to a sustained viral suppression and allows the recovery of 
thymic function, which in children is a pivotal event in immune reconstitution, and 
normalization of immunologic responses to non-HIV antigens [Luzuriaga K et al, J Virol 
2000; Chiappini E et al, AIDS 2006; Zanchetta M et al, Antivir Ther 2008; Goetghebuer 
T et al, AIDS 2009]. However, despite early ART treatment controls HIV replication and 
reduces viral load, it does not significantly prevent the establishment of a reservoir of 
latently infected cells that precludes virus eradication [Zanchetta M et al, Antivir Ther 
2008]. Therefore, perinatal infected children require life-long ART with the risk of 
important complications, including drug toxicities and adverse clinical events, consistent 
with those experienced by an aging population, including malignancies.  
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1.2.3 Cancer risk in children with perinatal HIV-infection 
HIV-infected children and adults have an higher cancer risk compared to the general 
population; in particular, Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and 
invasive cervical cancer (ICC) represent the cancers with the higher incidence rates 
among people with HIV/AIDS and are defined as AIDS-defining malignancies (ADM) 
[CDC; Morb Mortal Wkly Rep 1992]. The long-term HIV-induced immunodeficiency 
together with co-infection with oncogenic viruses (KS-associated herpes virus (KSHV), 
Epstein-Barr virus (EBV) and Human Papilloma Virus (HPV), etiological agents of KS, 
NHL and ICC, respectively) represent the explanation for the increased risk of ADM 
[Grulich AE et al, Lancet 2007].  
The impact of ART on cancer incidence in adulthood has been well described [Engels EA 
et al, AIDS 2006; Biggar RJ et al, J Natl Cancer Inst 2007; Grulich AE et al, Lancet 2007; 
Crum-Cianflone N et al, AIDS 2009; Simard EP et al, Cancer 2011], whereas it has been 
evaluated only by few studies in childhood [Kest H et al, Pediatr Infect Dis J 2005; 
Chiappini E et al, J Clin Oncol 2007; Alvaro-Meca A et al, Pediatr Infect Dis J 2011; 
Simard EP et al, Cancer Epidemiol Biomarkers Prev 2012]. Overall, epidemiological data 
suggest that with the widespread of ART, the incidence of ADM significantly decreased 
in both adults and children, due likely to partial immune restoration associated with an 
improved immune surveillance against oncogenic viruses [Biggar RJ et al, J Natl Cancer 
Inst 2007; Simard EP et al, Cancer Epidemiol Biomarkers Prev 2012]. In an Italian 
pediatric population of 1190 perinatal HIV-infected children, the ADM incidence 
decreased significantly from pre-ART to ART era [Chiappini E et al, J Clin Oncol 2007] 
(Table 2). The same trend was observed in an US study that analyzed cancer incidence 
between the pre-ART (1980-1995) and ART eras (1996-2007) in people diagnosed with 
AIDS during childhood (0-14 years): KS and NHL declined by 87% and 60%, 
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respectively in the ART era [Simard EP et al, Cancer Epidemiol Biomarkers Prev 2012]. 
Furthermore, a Spanish study that evaluated epidemiological trends of cancer diagnosed 
through 3 calendar periods (early-period ART: 1997-1999, middle-period ART: 2000-
2002, and late-period ART: 2003-2008), found that the rate of ADM diagnoses decreased 
significantly (from 9.1 to 3.6 to 1.0 per 1000 children/year) during the study period 
[Alvaro-Meca A et al, Pediatr Infect Dis J 2011] (Table 2). However, despite ART 
reduced ADM, the overall incidence of malignancies in HIV-infected children do not 
significantly differ between pre-ART and ART-era [Chiappini E et al, J Clin Oncol 2007; 
Alvaro-Meca A et al, Pediatr Infect Dis J 2011; Simard EP et al, Cancer Epidemiol 
Biomarkers Prev 2012] (Table 2). The improvement in long-term life expectancy has led 
to change the spectrum of cancer among people living with HIV, shifting from ADM to 
non-ADM. In the Spanish study cited before, the rate of overall non-ADM increased from 
0.6 to 5.0 to 8.7 cases of cancer per 1000 children/year during the early, middle and late 
ART eras [Alvaro-Meca A et al, Pediatr Infect Dis J 2011]. Malignant neoplasm of bone 
and articular cartilage, Hodgkin lymphoma (HD) and leiomyosarcoma were the cancers 
with the highest incidence [Simard EP et al, Cancer Epidemiol Biomarkers Prev 2012].  
The pathogenesis for the increased non-ADM incidence remains to be fully elucidated. 
Immunodepression was long considered to play pivotal role in the etiology of cancer; 
however, given the ART-associated immune recovery, the immunodeficiency is not 
sufficient to explain this excess risk. The dysfunction of immune system due to persistent 
immune activation, premature aging and immune senescence may be the drivers of non-
ADM [Deeks SG et al, Curr Opin Immunol 2012; Phillips AN et al, AIDS 2008].  
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Table 2. Epidemiologic data on cancer rate in HIV-infected children over time 
 
          
  
Incidence of cancer* 
Study population Study period All cancer ADM non-ADM 
     5840 1980-1995 5.59 4.70 0.65 
(United States)
1
 1996-2007 2.13 1.50 0.63 
     1190 1985-1995 4.49 2.97 1.69 
(Italy)
2
 1996-1999 4.09 2.60 1.48 
 
2000-2004 0.76 0.76 - 
     1307 1997-1999 9.70 9.10 0.60 
(Spain)
3
 2000-2002 8.70 3.60 5.00 
 
2003-2008 9.70 1.00 8.70 
          
     
 
*Incidence rates are per 1000 children/year 
From: 
1
 Simard EP et al, Cancer Epidemiol Biomarkers Prev 2012 
           
2
 Chiappini E et al, J Clin Oncol 2007 
                 3
 Alvaro-Meca A et al, Pediatr Infect Dis J 2011 
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1.2.4 Premature aging and immune senescence in HIV-infection 
Accumulating evidence suggest that HIV-infected people undergoing long-term ART 
tend to show an accelerated aging phenotype, that involves the immune system and leads 
to the increase in the frequency of non-AIDS-related complications (i.e. cardiovascular, 
liver and kidney diseases, non-ADM) [Deeks SG, Annu Rev Med 2011; Chiappini E et al, 
Cancer Lett 2014].  
The immunological alterations that characterized immune senescence both in 
physiological aging and in HIV infection have several common features, and in both 
conditions immune activation/inflammation play a crucial role in promoting the gradual 
decline of the functionality of the immune system [Desai S and Landay A, Curr 
HIV/AIDS Rep 2010]. These processes affect all aspects of immunity, but the T-cell 
compartment seems to be the most damaged. These changes are characterized by a 
reduction of number and function of hematopoietic stem cells, thymic involution, loss of 
naïve cells, progressive enrichment of terminally differentiated T-cells, shrinkage of the 
T-cell repertoire, reversed ratio of CD4
+
 to CD8
+
 cells and increased levels of pro-
inflammatory cytokines [Deeks SG, Annu Rev Med 2011].  
In the context of HIV infection, the virus replicates and releases virions into circulation. 
A low-grade, chronic and systemic replication occurs despite ART and causes a 
continuous stimulation of immune system and inflammatory response. In addition, the 
injury to the immune component of gastrointestinal mucosal surface, along with damage 
to the intestinal epithelial microenvironment with its antimicrobial functions, may affect 
systemic immune activation during the chronic phase of HIV infection through the release 
of microbial products into blood circulation [Brenchley JM et al, Nat Med 2006], a 
phenomenon defined as microbial translocation. The strong pressure on the immune 
system, exerted by viral antigens, leads to the clonal expansion of activated cells, 
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resulting in differentiation and accumulation of senescent cells with loss of effector 
functions and proliferative capacity [Desai S & Landay A, Curr HIV/AIDS Rep 2010; 
Khaitan A & Unumatz D, Curr HIV/AIDS Rep 2011] (Figure 6). Finally, the 
accumulation of senescent cells secreting proinflammatory factors results in a chronic 
inflammation status that leads to the development of age-related pathologies [Ovadya Y 
& Krizhanovsky V, Biogerontology 2014]. Indeed, the progressive decline of immune 
function may result in an impaired immune surveillance against tumor antigen favoring 
cancer onset. The chronic immune activation may also induce B-cell stimulation leading 
to an expansion of EBV-infected cells, thus increasing the risk of developing EBV-
associated malignancies [Petrara MR et al, Front Microbiol 2013]; both leiomyosarcoma 
and HD, two of the non-AIDS-defining cancers with higher incidence in the ART-era, are 
EBV-associated cancers [Bhatia K et al, Curr Opin Oncol 2012]. 
 
 
 
 
Figure 6. Accelerated aging model in HIV infection. [From Desai S & Landay A. Curr HIV/AIDS Rep 
2010] 
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Since telomeres have been postulated as a universal biological clock that shorten in 
parallel with aging of cells and whose attrition reflects cellular replication history and 
cellular senescence, shortening telomere length is considered the best marker of 
biological aging. Telomere length in peripheral blood mononuclear cells (PBMC) is 
representative of that of many tissues; indeed, intra-individual correlation between 
telomere lengths in different tissue is high [Daniali L et al, Nat Commun 2013]. Short 
telomere length has been associated with older age [Barrett EL and Richardson DS, 
Aging Cell 2011], age-related diseases and low survival in the general population 
[Brouilette SW et al, Lancet 2007; Cawthon RM et al, Lancet 2003; Heidinger BJ et al, 
Proc Natl Acad Sci U S A 2012]. Recently, short telomere length has been associated 
with HIV infection [Côté HC et al, PLoS One 2012; Pathai S et al, AIDS 2013]. 
Moreover, considering the capability of nucleoside reverse transcriptase inhibitors 
(NRTIs) to repress not only HIV reverse transcriptase but also human telomerase, it has 
been suggested that ART may be a potential factor contributing to HIV-associated 
accelerated shortening of telomere and premature aging [Liu X et al, Nucleic Acids Res 
2007; Hukezalie KR et al, PLoS One 2012; Leeansyah E et al, J Infect Dis 2013]. 
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The longitudinal substudy is in progress. 
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ABSTRACT 
 
Background. The challenge of immune senescence has never been addressed in elderly 
cancer patients. This study compares the thymic output and peripheral blood telomere 
length in 70≥ years old cancer patients. A longitudinal substudy is in progress to evaluate 
the impact of these markers on chemotherapy response and disease outcome. 
 
Patients and Methods. Fifty-two elderly cancer patients and 39 age-matched controls 
without personal history of cancer were enrolled. All patients underwent a 
Comprehensive Geriatric Assessment. Peripheral blood samples were studied for naïve 
and recent thymic emigrant (RTE) CD4
+
 and CD8
+
 cells by flow cytometry. T-cell 
receptor rearrangement excision circle (TREC) levels, telomere length and telomerase 
activity in peripheral blood cells were quantified by real-time PCR. Patients with 
colorectal cancer has been enrolled in the longitudinal substudy. 
 
Results. The percentages of CD8
+
 naïve and CD8
+
 RTE cells and TREC levels were 
significantly lower in cancer patients than in controls (p=0.003, p=0.004, p=0.031, 
respectively). Telomere lengths in peripheral blood cells were significantly shorter in 
cancer patients than in controls (p=0.046) and did not correlate with age in patients, 
whereas it did in controls (r=-0.354, p=0.031). Short telomere(≤median)/low 
TREC(≤median) profile was associated with higher risk of cancer (OR=3.68 [95%CI 
1.22-11.11]; p=0.021). Preliminary data from the longitudinal substudy suggested that 
after chemotherapy there was an increase of CD8
+
 terminally differentiated cells 
(p=0.031), and shortening of telomeres tended to higher in patients with stage III than in 
those with stage II. 
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Conclusions. Immune senescence is significantly worse in elderly cancer patients than in 
age-matched controls. The low thymic output and the shorter telomeres in peripheral 
blood cells of cancer patients may reflect a pre-existing condition which facilitates the 
onset of malignancies in elderly people and may impact the response to chemotherapy 
and the disease outcome. 
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1. INTRODUCTION 
People over 65 years old are the fastest-growing age bracket in the population and will 
account for an estimated 20% of Americans and 25% of Europeans by the year 2030 
[Fries JF, Ann Intern Med 2003]. The incidence of malignancies increases with age, so 
the number of cancers in the elderly is expected to increase significantly in years to come 
[American Cancer Society, 2012].
 
Several studies have shown that elderly patients are 
less likely to be treated according to guidelines, and their under-treatment may be 
detrimental to both survival and quality of life [Sargent DJ et al, N Engl J Med 2001; 
Bouchardy C et al, J Clin Oncol 2003; Dale DC, J Support Oncol 2003; Ng R et al, Clin 
Lung Cancer 2005]. Elderly cancer patients may benefit from chemotherapy just as much 
as younger adults, but at a higher risk of hematological toxicity [Muss HB et al, JAMA 
2005; Hurria A et al, J Natl Compr Canc Netw 2012; Muss HB et al, J Clin Oncol 2007]. 
Better understanding of the physiological and functional changes that occur with aging 
will enable to improve strategies for treating elderly cancer patients. Since the aging 
process coincides with a gradual decline in the functional reserve of multiple organ 
systems [Balducci L, J Support Oncol 2003] the search for laboratory markers of 
biological aging and organ reserve should be a priority of clinical research in the field of 
geriatric oncology. 
 
Over a lifetime, the immune system undergoes profound remodeling process with major 
impact on health and survival [Grubeck-Loebenstein B et al, Aging Clin Exp Res 2009; 
Fulop T et al, Ann N Y Acad Sci 2010]. Thymic involution and diminished output of T 
lymphocytes are thought to be among the major factors contributing to the loss of 
immune function with age [Berzins SP et al, J Exp Med 1998]. T-cell output begins to 
decline exponentially from early in life, and at 75 years of age the immune repertoire 
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appears to be severely impaired [Douek DC et al, Nature 1998; Naylor K et al, J Immunol 
2005]. However, recent data suggest that the thymus may remain active even late in life, 
supplying functional T cells to the periphery [Nasi M et al, Aging Cell 2006; Mitchell 
WA et al, Clin Exp Immunol 2010]. 
 
Measuring T-cell receptor rearrangement excision circle (TREC) levels in peripheral 
blood lymphocytes has been suggested as a method for quantifying thymic output [Douek 
DC et al, Nature 1998; Zhang L et al, J Exp Med 1999; Ometto L et al, AIDS 2002; De 
Rossi A et al, J Infect Dis 2002]. TRECs are generated by T-cell receptor gene 
rearrangement and maintained in thymic emigrant cells as DNA episomes. Because 
TRECs are not duplicated during mitosis, their concentration is diluted out with each cell 
division. The frequency of recent thymic emigrant (RTE) cells in peripheral blood, 
identified by the marker CD31
+
 among the CD45RA
+
 naïve T cells [Kimmig S et al, J 
Exp Med 2002], decreases with aging and correlates well with the decline in TREC levels 
[Kohler et al, Eur J Immunol 2005; Junge S et al, Eur J Immunol 2007]. Very little is 
known about the relationship between TRECs and cancer, especially in elderly patients. 
One study on head and neck cancer patients, including just a few ≥70 years old, showed 
that the age-associated decrease of TREC numbers and naïve T lymphocytes was 
significantly greater in cancer patients than in controls, suggesting altered lymphocyte 
homeostasis in the former [Kuss I et al, Clin Immunol 2005]. 
 
The immune system function depends largely on its capacity for extensive cell division 
and clonal lymphocyte expansion. Telomere length, and its regulation by telomerase have 
attracted considerable attention, due to their potential roles in controlling cell replication 
[Blackburn E et al, Nat Med 2006]. Telomeres are capping end structures of eukaryotic 
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chromosomes essential for protecting chromosome integrity [Blasco MA, Nat Rev Genet 
2005]. Telomeres are progressively shortened during each cell division due to end-
replication problems of DNA polymerase; when a critical length is reached, the cell 
undergoes cycle arrest and apoptosis [Blasco MA, Nat Rev Genet 2005]. Permanent cell 
growth relies on telomere maintenance, and certain human cell subsets, as well as most 
cancer cells, have telomerase activity which enables telomere elongation [Dolcetti R & 
De Rossi A, Med Res Rev 2012]. Despite their telomerase activity, most tumor cells have 
shorter telomeres than the corresponding normal tissues, and there is a relationship 
between short telomeres and genetic instability [Garcia-Aranda C et al, Cancer 2006; 
Rampazzo E et al, Br J Cancer 2010]. Since telomere shortening reflects cell turnover and 
exposure to oxidative and inflammatory damage, which are crucial processes of 
biological aging, it has been suggested that telomere length serves as an indicator of aging 
process [Wong JMY & Collins K, Lancet 2003; Aviv A, J Gerontol A Biol Sci Med Sci 
2006; Baird DM, Exp Gerontol 2006]. Telomere shortening in peripheral blood cells has 
been associated with a number of chronic diseases, such as coronary heart disease, 
hypertension, dementia, obesity, insulin resistance, and osteoporosis. However, two 
clinical trials failed to confirm any relationship between telomere length and frailty 
syndrome in elderly non-cancer patients [Woo J et al, Mech Ageing Dev 2008; Collerton 
J et al, Mech Ageing Dev 2012]. 
 
Several studies have investigated the relationship between telomere length in peripheral 
blood cells and cancer risk and outcome. Although few manuscript report that longer 
telomere length is a risk factor [Lan Q et al, PLoS One 2013; Svenson U et al, Cancer Res 
2008], most of the studies indicate that short telomere lengths are associated with a cancer 
risk and/or worse prognosis [Bojesen SE et al, Nat Genet 2013; Martinez-Delgado B et al, 
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J Med Genet 2012; Riegert-Johnson DL et al, Int J Biol Markers 2012; Shao L et al, J 
Urol 2007; Wu X et al, J Natl Cancer Inst 2003; Qu F et al, Mol Oncol 2014; Chen Y et 
al, Ann Oncol 2014]. To date, however, telomere length in peripheral blood cells has been 
measured in elderly non-cancer patients and younger cancer patients, but no data are 
available for elderly cancer patients.  
 
In this study, we present the results of a prospective observational study providing the 
first description of immune senescence markers and frailty scores in elderly cancer 
patients and age-matched controls. Furthermore, we report the preliminary results of the 
ongoing longitudinal substudy planned to evaluate the impact of these markers on 
chemotherapy response and/or risk of tumor relapse. 
 
2. MATERIAL and METHODS 
2.1 Study design and study population 
Patients enrolled in this prospective observational study were aged ≥70 years, with stage 
I-III breast or colorectal cancer, diagnosed during the previous 2 months and radically 
resected, consecutively admitted to the Medical Oncology Units from September 2010 to 
March 2012. Controls included patients ≥70 years old with no personal history of cancer, 
consecutively admitted to the Geriatric Clinic. For both groups, the exclusion criteria 
were: any hematological disorders, chronic diseases requiring immunosuppressive 
treatment, prior immunodeficiency, blood transfusion ≤4 weeks before blood sampling, 
active infectious diseases, extremely severe comorbidities suggesting a life expectancy <6 
months, or severe cognitive impairment hampering communication with the physician.  
A subgroup of patients with colorectal cancer have been enrolled in the longitudinal 
substudy. 
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The study was approved by the institutional Ethics Committee and conducted in 
accordance with the Helsinki Declaration and Good Clinical Practice guidelines. Written 
informed consent was obtained from all patients. 
 
2.2 Clinical assessment 
Complete demographic and clinical details were collected at baseline for each patient 
(Table 1). At the first visit, both cases and controls underwent traditional comprehensive 
geriatric assessment (CGA) administered by a multidisciplinary team, including medical 
oncologist, geriatrician and psychologist. As reported elsewhere [Basso U & Monfardini 
S, Eur J Cancer Care 2004], the CGA included Activities of Daily Living (ADL), 
Instrumental Activities of Daily Living (IADL), Short Portable Mental Status 
Questionnaire (SPMSQ), and the Mini Mental Status Examination (MMSE). 
Comorbidities and their severity were studied according to the Cumulative Illness Rating 
Scale-Comorbidity Index (CIRS-CI) and Cumulative Illness Rating Scale-Severity Index 
(CIRS-SI) [Conwell Y et al, J Am Geriatric Soc 1993]. Affective status was assessed with 
the Geriatric Depression Scale (GDS) [Yesavage JA et al, J Psychiatr Res 1983]. 
Nutritional status was explored with the Mini Nutritional Assessment (MNA) [Guigoz Y 
& Vellas B, Nutr Workshop Ser Clin Perform Programme 1999]. Social aspects included 
household composition, institutionalization, amount of assistance provided by a caregiver. 
The number of drugs taken by patients for concomitant diseases was also recorded. The 
CGA results were interpreted as previously reported by Balducci [Balducci L, J Support 
Oncol 2003], classifying patients as fit, vulnerable or frail. A multidimensional prognostic 
index (MPI) score was also calculated based on findings for the ADL, IADL, SPMSQ, 
CIRS-CI, CIRS-SI, MNA, number of drugs and social conditions, assuming a low, 
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moderate and high mortality risk for MPI ≤0.33, 0.34-0.66, >0.66, respectively [Pilotto A 
et al, Rejuvenation Res 2008; Giantin V et al, J Geriatric Oncol 2013]. 
 
2.3 Biomarker analyses 
Peripheral blood samples were collected at the time of enrollment, prior to any 
oncological medical treatment (endocrine therapy, chemotherapy, radiotherapy or 
immune therapy). In the longitudinal substudy, samples were collected at the end of 
adjuvant chemotherapy treatment and/or at tumor relapse; the median period of follow-up 
was 22 [20-28] months. Samples were analyzed for the standard blood parameters (Table 
1S, Supplementary data), for Cytomegalovirus (CMV) and for the following tests. 
 
2.4 Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood by 
centrifugation on a Ficoll-Paque gradient [Freguja R et al, Clin Exp Immunol 2011]. Cells 
were stained with the following labeled monoclonal antibodies (mAbs): anti-CD3 (FITC), 
anti-CD4 (PerCP), anti-CD8 (PerCP), anti-CD31 (PE) and anti-CD45RA (APC). 
Appropriate isotypic controls (mouse IgG1-PE and mouse IgG2b-APC) were used to 
assess non-specific staining. All samples were analysed by four-color flow cytometry on 
a fluorescence-activated cell sorter (FACS)Calibur (Becton-Dickinson) [Freguja R et al, 
Clin Exp Immunol 2011]. Data were processed with CellQuest Pro Software (Becton-
Dickinson) and analysed using Kaluza
®
 Analysis Software v.1.2 (Beckman Coulter). 
Anti-CD45RA and anti-CD27 were used to identify, within CD3
+
CD4
+
 and CD3
+
CD8
+
 
gates, naïve (CD45RA
+
CD27
+
), central memory (CD45RA
-
CD27
+
), effector memory 
(CD45RA
-
CD27
-
) and terminally differentiated memory (CD45RA
+
CD27
-
) cells. 
Moreover, anti-CD45RA and anti-CD31 were used to identify recent thymic emigrant 
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(RTE) (CD45RA
+
CD31
+
), and anti-CD28 and anti-CD57 to identify senescent cells 
(CD28
-
CD57
+
). 
 
2.5 TREC quantification  
Thymic output in PBMC was studied by measuring TREC levels by real-time polymerase 
chain reaction (PCR), exactly as described previously [Ometto L et al, AIDS 2002; De 
Rossi A et al, J Infect Dis 2002]. TREC levels were expressed as the number of TREC 
copies per 10
5 
PBMC [De Rossi A et al, J Infect Dis 2002; Anselmi A et al, Clin Exp 
Immunol 2007]. 
 
2.6 Telomere length measurement by quantitative real-time PCR  
Telomere length in PBMC was determined by real-time PCR exactly as described 
elsewhere [Rampazzo E et al, Br J Cancer 2010; Rampazzo E et al, Haematologica 2012], 
and values were expressed as relative telomere/single-copy gene (T/S) ratio [Rampazzo E 
et al, Br J Cancer 2010]. 
 
2.7 Telomerase activity quantification 
Telomerase activity was quantified by real-time PCR, as described elsewhere [Rampazzo 
E et al, Haematologica 2012] and expressed in relative units (RU). 
 
2.8 Irradiation of PBMC and detection of DNA-damage by flow cytometry 
After isolation of PBMC by Ficoll-Paque gradient, cells (~8*10
6
) were cultured in RPMI 
medium supplemented with 10% fetal calf serum (FCS, Life Technologies), 10 ng/ml IL-
2 (Roche), 2mM L-glutamine (Gibco) and 50 ug/ml Gentamycin (Sigma) (standard 
medium) at 37°C in 5% CO2, in 6-well plate for 12 hours before y-irradiation. Following 
the removal of ~10
6 
PBMC (untreated control), the remaining cells were irradiated to a 
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dose of 2.5 Gy using y-radiation from a 
137
Cesium source (CisBIO International, France) 
at room temperature and were immediately incubated in 12-well plate in standard medium 
at 37°C in 5% CO2; aliquots of ~10
6 
PBMC cells were taken 1, 5 and 24 h post-
irradiation. Cells were fixed in 4% paraformaldehyde (Sigma) for 10 min at 37°C, chilled 
on ice for 1 min, washed in PBS, permeabilized with 90% methanol in 0.5% bovine 
serum albumin (BSA; Sigma)-PBS, and kept at -20°C for 1 h. Cells were washed three 
times with 0.5% BSA-PBS and incubated in blocking buffer [PBS supplemented with 8% 
FCS, 0.1 g/L RNAseA (Life Technologies), 10 mM NaF (Sigma) and 1 mM NaVO3  
(Sigma), 0.25 g/L salmon sperm DNA (Sigma), 0.2% Triton X-100 (Roche)] for 1 h prior 
to y-H2AX staining with the AlexaFluor-488 mouse anti-H2AX (pS139) antibody (BD 
Pharmigen) diluted in blocking buffer for 1 h at room temperature. Cells were washed 
twice in 0.5% BSA-PBS and resuspended in PBS. Isotype antibody was included as a 
background reference. A minimum of 100000 cells were acquired using a FACSCalibur 
(Becton-Dickinson). Cellular debris were excluded from the analysis by gating a forward 
scatter versus side scatter plot. Analysis of flow cytometry data was conducted using the 
CellQuest Pro Software (Becton-Dickinson). Percentage of y-H2AX positive cells and 
median fluorescence intensity were calculated at each time point. 
 
2.9 Statistical analysis 
Differences in geriatric parameters between groups were examined with the Mann-
Whitney test for non-parametric data and Pearson’s χ2 test with odds ratios (OR) and 95% 
confidence intervals (CI) for nominal data (CGA, MPI, ADL, IADL). The Mann-Whitney 
test was used to compare subsets of lymphocytes, TREC levels and telomerase activity. 
Student’s t-test was used to compare the telomere lengths. Correlations between age and 
TREC levels, or telomere length in both groups were analysed with Pearson’s χ2 test. 
46 
 
Spearman’s rank correlation was used to analyse associations between geriatric 
parameters and TREC levels, telomere lengths or telomerase activity. TREC levels and 
telomere length were analysed also as dichotomous variables (cut-off: ≤median) and OR 
were estimated using logistic regression model. All statistical analyses were performed 
using SPSS software, version 19 (SPSS Inc.). All p-values were two-tailed, and were 
considered significant when lower than 0.05. 
 
3. RESULTS 
3.1 Characteristics of study population  
Ninety-one patients, 52 with cancer (26 breast and 26 colorectal cancer) and 39 controls, 
were enrolled in the study. Their demographic and clinical characteristics are listed in 
Table 1. There were more females in the control group (82.1%) than among the cancer 
patients (63.5%); the latter had better Karnofsky performance status than controls. As 
established by the study protocol, before enrollment, cancer patients underwent a 
thorough radiological assessment to rule out metastases. According to the TNM staging 
system, 16 patients (30.8%) had stage I, 33 (63.5%) had stage II, and 3 (5.7%) had stage 
III disease. Thirty-one patients were prescribed the same adjuvant therapy as for younger 
adults, according to good clinical practice, 18 patients received an adapted treatment, due 
to problems detected at the CGA, and 3 were given no adjuvant therapy, due to frailty 
detected at the CGA and were only followed up.  
 
3.2 Comprehensive geriatric assessment 
All cancer patients and controls underwent the full CGA; 17.3% of the former and 43.6% 
of the latter were classified as frail (OR=0.29, 95% CI 0.10-0.82), while the proportion of 
vulnerable patients in the two groups did not differ significantly (Table 2). 5.8% of cancer 
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patients and 23.1% of controls had a moderate MPI (OR=0.20, 95% CI 0.05-0.79), and 
only one control had a severe MPI score. When MPI was calculated as a continuous 
variable, the median score was significantly lower for cancer patients than for controls 
(Table 2). In ADL and IADL, cancer patients tended to have preserved greater physical 
autonomy than controls, although the difference was not statistically significant (Table 2). 
Controls had better cognitive status in both the MMSE and SPMSQ, but their burden of 
associated diseases (as shown by CIRS-CI and CIRS-SI) was higher, as was their use of 
drugs for these comorbidities (Table 2). 
 
3.3 Standard hematological and biochemical parameters  
The hematological parameters of cancer patients and controls differed only in their 
platelet count (Table 1S, Supplementary data). Controls had significantly lower levels of 
nutritional markers, such as total plasma proteins, triglycerides, and LDL-cholesterol; 
CRP and IL-6 were significantly higher in controls than in cancer patients (Table 1S, 
Supplementary data). The overall prevalence of CMV-IgG seropositive individuals was 
96.7%. Antibodies against CMV were found in 49 (94.2%) of cancer patients and 39 
(100%) of controls. No statistical difference was found between CMV antibody titers 
between the groups (p=0.498) (Table 1S, Supplementary data). 
 
3.4 Immune senescence markers 
Cancer patients and controls had comparable percentages of total CD4
+
 lymphocytes, 
naïve CD4
+
CD45RA
+
 and RTE CD4
+
CD45RA
+
CD31
+
 cells (Table 3). By contrast, the 
median (interquartile) percentages of naïve CD8
+
CD45RA
+
CD27
+
 and RTE 
CD8
+
CD45RA
+
CD31
+
 cells were significantly lower in cancer patients than in controls 
(16.7% [9.3-25.2] versus 24.6% [14.7-33.5]; p=0.003) and (34.2% [24.7-46.4] versus 
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44.9% [36.0-50.7]; p=0.004), respectively (Table 3). Notably, the lower percentage of 
CD8
+
 naïve cells in cancer patients was compensated by a higher expansion of CD8
+
 
memory cells; thus, cancer patients and controls did not differ in terms of their 
percentages of total CD8
+
 cells (Table 3). In particular, among the CD8
+
 cell subsets, the 
CD45RA
-
CD27
-
 (effector memory) cells were found to be significantly higher in cancer 
patients than in controls (21.7% [12.7-31.7] versus 16.3% [10.4-25.0]; p=0.042). The 
imbalance in favor of the CD8
+
 memory cell subset in cancer patients was evident even 
when the absolute cell count was considered (not shown). For a few subjects with 
available frozen samples (11 cancer patients and 8 controls), markers of immune 
senescence (CD28
-
CD57
+
) were investigated. Cancer patients and controls exhibited 
percentages of CD4
+
CD28
-
CD57
+
, but CD8
+ 
cells with senescent phenotype tended to be 
higher in the former (p=0.082) (Table 3S, Supplementary data). 
 
TREC levels in PBMC were significantly higher in controls than in cancer patients (25.0 
[14.0-56.0] versus 16.0 [7.7-31.5] TREC copies/10
5
 PBMC; p=0.031) (Table 3). TREC 
levels decreased significantly with increasing age in cancer patients (r=-0.478; p<0.001), 
while did not correlate with age in controls (r=0.071; p=0.677) (Figure 1A). 
The mean telomere length in PBMC was significantly lower in cancer patients than in 
controls; the former had a mean (± standard deviation (SD)) telomere length of 1.09±0.31 
T/S versus 1.22±0.30 T/S in controls, p=0.046 (Table 3). Telomere length correlated 
inversely with age in controls (r=-0.354, p=0.031), but not in cancer patients (r=-0.011, 
p=0.938) (Figure 1B). Telomerase activity was significantly higher in cancer patients, 
being detected in 38/52 patients (73.1%; median value 14.6 RU) and 20/38 controls 
(52.6%; median value 1.4 RU); p=0.003. Telomerase activity was not influenced by age 
in either group.  
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TREC was defined as high and low, and telomere length as long or short according to 
their value above and below the median, respectively. Subjects with TREC low/telomere 
short profile were at  higher risk of cancer than  subjects with only low TREC or short 
telomere (Table 4). 
 
3.5 Relationship between TREC levels, telomere length and geriatric characteristics  
In the control group, the CIRS-SI was the only tool which revealed a significant positive 
association with TREC level (r=0.45, p=0.01) and telomere length (r=0.35, p=0.03), 
whereas it had a significant negative correlation with the number of drugs taken for 
concomitant diseases (r=-0.39, p=0.02) (Table 2S, Supplementary data). No relationship 
emerged between telomere length, thymic output and geriatric features of cancer patients 
(Table 2S, Supplementary data). Neither a classification of unfitness at CGA (not shown) 
nor the MPI score (Table 2S, Supplementary data) correlated significantly with the 
thymic output or telomere length in either group. Among the controls, TREC levels 
correlated positively with IL-6 (r=0.34, p=0.04), and negatively with total plasma protein 
levels (r=-0.38, p=0.02). Neither of these correlations emerged in the cancer patients (data 
not shown). 
 
3.6 Preliminary results from the longitudinal substudy 
Twenty-two patients have been already enrolled in this substudy. Eight patients received 
capecitabine plus oxaliplatin, 1 capecitabine plus bevacizumab, 8 capecitabine alone for 6 
months while 5, all with stage II disease, received no adjuvant chemotherapy. Four 
patients suspended therapy before the deadline due to poor tolerability and/or onset of 
cardiovascular complications. Three patients had a relapse: one with stage II disease (no 
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adjuvant chemotherapy) and two with stage III (both with a complete chemotherapy 
treatment). 
 
Overall, telomere length tended to decrease during the follow-up period (T/Sbaseline 
1.23±0.28 versus T/Sfollow-up 1.14±0.25; p=0.201), even if at not significant level. At 
baseline, telomere length was not associated with tumor staging, being T/S of 1.20±0.26 
and 1.27±0.32 for stage II and III respectively (p=0.300), but their shortening at follow-
up tended to be higher in patients with stage III than in those with stage II (∆baseline-follow-up 
T/S 0.13 versus 0.07). The ΔT/S of 3 patients with tumor relapse were: 0.15, 0.05 and -
0.14, respectively; the low number and the heterogeneity (stage disease and treatment) did 
not allow to draw any conclusions. TREC levels tended to be lower in samples at follow-
up compared to baseline (6 [3-18] versus 10 [6-22] TREC copies/10
5 
PBMC; p=0.161). 
These results are in agreement with phenotypic analysis of peripheral blood cells. 
Frequencies of CD4
+
 and CD8
+
 naïve T cell did not change during follow-up period. 
Conversely, within the CD8
+
 memory cell subset, we found a shift of cells from effector 
(CD45RA
-
CD27
-
) to terminally differentiated (CD45RA
+
CD27
-
) phenotype (Figure 2). 
Moreover, senescent cells tended to be more expanded at follow-up than at baseline 
(63.0% [57.9-73.5] versus 58.5% [46.5-64.0]; p=0.099). The higher frequencies of these 
subsets may explain the tendency of shorter telomere length in samples at follow-up. 
The higher levels of memory cells in elderly cancer patients, both before and after 
treatment, is important. It is known that DNA-damage recognition and repair efficiency 
varies between memory and naïve cells [Scarpaci S et al, Mech Ageing Dev 2003; 
Cossarizza A et al, Mech Ageing Dev 1996]. In a preliminary experiment, we analyzed 
the DNA-damage repair in PBMC exposed to a dose of 2.5 Gy using y-radiation from a 
137
Cesium source. By flow cytometric assay, we found that the level of y-H2AX, a robust 
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marker of cellular double strand breaks [d'Adda di Fagagna F et al, Nature 2003], was 
higher in untreated PBMC from cancer patients than in those from controls, suggesting a 
more unstable genome in the former. Soon after irradiation, the level of y-H2AX 
increased in both groups, but at 24 h it remained higher in cancer patients than in controls 
(Figure 3), suggesting a lower efficiency in DNA repair process in the former [Banáth JP 
et al, BMC Cancer 2010].  
 
4. DISCUSSION 
This is the first study aiming to shed light on two essential aspects of the aging process 
(thymic output and telomere length in peripheral blood cells) in elderly cancer patients. 
We found that 70- to 92-year-old cancer patients had significantly lower TREC levels, 
lower percentages of naïve and RTE CD8
+
 T lymphocytes, and a more expanded CD8
+
 
memory cell subset than age-matched controls. These results are partially consistent with 
those of a small trial in which head and neck cancer patients (most of them under 70-
years-old) revealed lower TREC levels than controls [Kuss I et al, Clin Immunol 2005]. 
The expansion of memory CD8
+ 
cells, particularly those with effector phenotype, is also 
consistent with the findings of two recent studies conducted on breast cancer patients 
[Hueman MT et al, Cancer Immunol Immunother 2007; Poschke I et al, Int J Cancer 
2012]. The shift from naïve T cells to memory cells was probably due to greater 
stimulation by tumor antigens; as CD8
+
 T cells are the key components of tumor immune 
surveillance, the tumor-induced dysfunction may be more evident in the CD8-cell subset 
than in the CD4
+ 
T-cell compartment [Klebanoff CA et al, Immunol Rev 2006; Williams 
MA & Bevan MJ, Annu Rev Immunol 2007].  
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Our findings confirm reports by other authors that thymic activity does not stop 
completely beyond 70 years of age [Nasi M et al, Aging Cell 2006; Mitchell WA et al, 
Clin Exp Immunol 2010]. Notably, while TREC levels in cancer patients dropped 
significantly with increasing age, they remained relatively constant in controls. Thymic 
output may compensate for the loss of peripheral blood lymphocytes in elderly patients, 
but this homeostatic phenomenon seems to disappear in cancer patients. In our study, the 
control group included a higher proportion of frail patients, with higher average MPI 
scores and more chronic diseases and comorbidities than the cancer patients. Levels of 
pro-inflammatory cytokine IL-6 were also significantly higher in controls than in cancer 
patients. Systemic inflammation and loss of peripheral blood cells may stimulate thymic 
output, which plays an important role in immunological homeostasis. In fact, TREC 
levels did correlate significantly with CIRS-CI in controls group, but not in cancer 
patients. The imbalance between the two groups in terms of their geriatric conditions 
reinforces the magnitude of the difference observed for TREC levels between cancer 
patients and controls. While the hypothesis of immune homeostasis may justify a higher 
thymic output in controls, the lower age-related TREC levels seen in cancer patients may 
point to a pre-existing condition, favoring immune escape and the onset of malignant 
disease.  
 
In agreement with the lower percentage of CD8
+ 
naïve and RTE cells in cancer patients 
than in controls, the former tended to have a higher percentage of CD8
+ 
immune 
senescent cells. Several data indicate that latent CMV infection leads to significant 
changes in the CD8
+ 
repertoire, and it may be an important driver of immune senescence 
[Almanzar G et al, J Virol 2005; Solana R et al, Immun Ageing 2012]. The above results 
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are unlikely to be due to CMV infection, because all except three cancer patients were 
CMV-positive and with similar titers of anti-CMV antibodies. 
As regards telomere length, there are many data available on the relationship between 
telomere length and aging-associated changes and chronic [Wong JMY & CollinsK , 
Lancet 2003; Aviv A, J Gerontol A Biol Sci Med Sci 2006; Baird DM, Exp Gerontol 
2006], but data are lacking for elderly cancer patients. Our study showed that cancer 
patients’ telomeres in PBMC are significantly shorter than those seen in controls. In 
addition, while control patients’ telomeres become shorter with age, as expected 
according to previous studies [Blasco MA, Nat Rev Genet 2005; Der G et al, PLoS One 
2012; Steenstrup T et al, Eur J Epidemiol 2013;, no such relationship between age and 
telomere length was seen in our cancer patients. This difference cannot be explained by 
lower telomerase activity, because it was detected in the PBMC of most cancer patients. 
The fact that controls scored worse on the severity and comorbidity indexes than cancer 
patients clearly highlights the magnitude of the difference in telomere length between the 
two groups. 
Several studies have found shorter telomeres in tumor cells than in surrounding non-
cancer cells [Rampazzo E et al, Br J Cancer 2010; Bisoffi M et al, Int J Cancer 2006], but 
the intriguing finding of shorter telomeres in PBMC cannot be explained by the presence 
of cancer cells in peripheral blood. Our cancer patients had radically-resected early breast 
or colorectal cancer, and had undergone through radiological assessment to exclude both 
persistent local disease and distant metastases. As reported elsewhere [Franken B et al, 
Breast Cancer Res 2012; Shimada R et al, Oncol Rep 2012], the number of epithelial cells 
detectable in the peripheral blood on patients with early breast or colorectal cancer is so 
small that it cannot influence telomere length or telomerase activity. We surmised that our 
control patients’ longer telomeres are related to their higher proportion of naïve CD8+ 
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cells. To explore this issue, we estimated telomere length separately in CD8
+
 naïve and 
CD8
+
 memory cells from 3 cancer patients: the two subsets had a similar telomere length, 
indicating that the shorter telomeres cannot be explained by an excessive 
replication/expansion of the memory cell subset (not shown). We therefore suggest that 
telomere length in peripheral blood cells reflects the more advanced biological aging of 
the immune system in cancer patients than in controls, a pre-existing condition which 
facilitates the onset of cancer in the former. In addition, the analysis of y-H2AX 
expression in PBMC, before and after exposure to a source of y-radiation, revealed that 
cancer patients, have a higher baseline level of DNA-damage and a lower capacity to 
repair it compared to controls. Because genomic instability is a driver of tumorigenic 
process, subjects with higher genomic instability are at a greater risk for developing 
cancer and relapse.  
In summary, from the exploratory study emerged that elderly cancer patients have 
significantly lower thymic output and shorter telomeres in their peripheral blood cells 
than age-matched non-cancer patients; these results indicate that immune senescence may 
hamper the ability of the immune system to prevent cancer initiation and/or control tumor 
progression. Moreover, considering that the effective immune responses are dependent 
upon optimal lymphocyte division and clonal expansion, and that immune senescence 
may contribute to chemotherapy response and outcome of disease, the search of these 
markers may be useful to predict tumor onset and treatment response. 
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Table 1. Demographic and clinical characteristics of cancer patients and controls 
 
  
  
All  
patients,  
n (%) 
Cancer 
 patients,  
n  (%) 
Controls,  
n (%) 
Age (yrs)    
 
n. 
Median, range 
91 (100) 
81, 70-92 
52 (57.2) 
81, 72-92 
39 (42.8) 
80, 70-91 
Gender    
 
Male 
Female 
26 (28.6) 
65 (71.4) 
19 (36.5) 
33 (63.5) 
7 (17.9) 
32 (82.1) 
Performance status (ECOG)    
 
0-1 
≥2 
83 (91.2) 
8 (8.8) 
51 (98.1) 
1 (1.9) 
32 (82.1) 
7 (17.9) 
Social Condition 
                    Home 
                    Nursing home  
  
90 (98.9) 
1 (1.1) 
 
51 (98.1) 
1 (1.9) 
 
39 (100) 
0 (0.0) 
 
Type of Assistance 
                    Alone 
                    Family 
                    Others 
 
 
 
23 (25.3) 
59 (64.8) 
9 (9.9) 
 
9 (17.3) 
38 (73.1) 
5 (9.6) 
 
14 (35.9) 
21 (53.8) 
4 (10.3) 
Caregiver Assistance (hours/day) 
                    Median time, range  
 
24, 2-24 
 
24, 2-24 
 
24, 3-24 
Tumor Stage (TNM) 
                    I 
                    II 
                    III 
 
 
 
- 
- 
- 
 
16 (30.8) 
33 (63.5) 
3 (5.7) 
 
- 
- 
- 
Modality of Diagnosis 
                         Symptoms/Self examination 
                   Screening 
                   Incidental diagnosis 
 
 
 
- 
- 
- 
 
40 (76.9) 
9 (17.3) 
3 (5.8) 
 
- 
- 
- 
Therapeutical Choice 
                  Adjuvant therapy as for 
                  younger adults               
                  Adapted treatment 
                  No adjuvant therapy 
 
 
 
 
- 
- 
- 
 
 
31 (59.6) 
18 (34.6) 
3 (5.8) 
 
 
- 
- 
- 
Agreement to Proposed Therapy 
                  Ready 
                  Patient refusal 
 
 
 
- 
- 
 
51 (98.1) 
1 (1.9) 
 
- 
- 
Cause of Admission to hospital/ 
Outpatient Services 
                  Cardiovascular disease 
                  Peripheral deep venous 
                  thrombosis 
                  Gastrointestinal inflammatory 
                  disorders or bleeding 
                  Screening of osteoporosis 
                  with no active comorbidity 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
- 
 
- 
 
- 
 
- 
 
 
18 (46.2) 
 
4 (10.2) 
 
5 (12.8) 
 
12 (30.8) 
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Table 2. Scores of geriatric tools in cancer patients and controls 
 
 
 
Geriatric Tool All patients Cancer patients Controls OR (95% CI) p-value 
CGA, n (%) 
      Fit 
      Vulnerable 
      Frail 
MPI, n (%) 
      Low 
      Moderate 
      Severe 
MPI 
      Median, range 
Dependencies in ADL, n (%) 
      No  
      ≥1  
Dependencies in IADL, n (%) 
     No 
      ≥1  
MMSE 
     Median [IQR] 
SPMSQ 
     Median [IQR] 
CIRS-CI 
    Median [IQR] 
CIRS-SI 
    Median [IQR] 
GDS 
    Median [IQR] 
BMI 
    Median [IQR] 
Drugs for concomitant diseases 
   Median [IQR] 
 
37 (40.7) 
28 (30.7) 
26 (28.6) 
 
78 (85.7) 
12 (13.2) 
1 (1.1) 
 
0.25, 0.00-0.69 
 
71 (78.0) 
20 (22.0) 
 
57 (62.6) 
34 (37.4) 
 
27.1 [24.4-28.4] 
 
1.0 [0.0-2.0] 
 
3.0 [1.0-4.0] 
 
1.5 [1.3-1.6] 
 
3.0 [1.0-6.0] 
 
25.7 [24.0-27.4] 
 
5 [3-6] 
 
24 (46.2) 
19 (36.5) 
9 (17.3) 
 
49 (94.2) 
3 (5.8) 
0 (0.0) 
 
0.19, 0.00-0.44 
 
44 (84.6) 
8 (15.4) 
 
36 (69.2) 
16 (30.8) 
 
26.2 [24.4-27.3] 
 
1.0 [0.0-2.0] 
 
2.0 [1.0-3.0] 
 
1.4 [1.2-1.5] 
 
3.0 [1.2-6.0] 
 
25.8 [24.2-26.9] 
 
4 [2-5] 
 
13 (33.3) 
9 (23.1) 
17 (43.6) 
 
29 (74.3) 
9 (23.1) 
1 (2.6) 
 
0.25, 0.06-0.69 
 
27 (69.2) 
12 (30.8) 
 
21 (53.8) 
18 (46.2) 
 
28.3 [26.4-29.3] 
 
0.0 [0.0-2.0] 
 
3.0 [2.0-4.0] 
 
1.6 [1.4-1.8] 
 
3.0 [1.0-6.0] 
 
25.0 [23.0-28.6] 
 
5 [4-8] 
 
1 
1.14 (0.40-3.24) 
0.29 (0.10-0.82) 
 
1 
0.20 (0.05-0.79) 
<0.01 
 
- 
 
1 
0.41 (0.15-1.14) 
 
1 
0.52 (0.22-1.23) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
0.801 
a
 
0.020 
 a
 
 
 
0.022 
 a
 
ns
  a
 
 
0.001
 a
 
 
 
0.790
 a
 
 
 
0.133
 a
 
 
0.001
 b
 
 
0.013
 b
 
 
0.032
 b
 
 
<0.001
 b
 
 
0.888
  b
 
 
0.911
b
 
 
0.003
 b
 
                   a Pearson's χ2 or Fisher test;  b Mann-Whitney U test 
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Table 3. Thymic output and telomere length in cancer patients and controls 
 
 
Parameter 
 
All patients 
Median [IQR] 
Cancer patients 
Median [IQR] 
Controls 
Median [IQR] 
 
p-value 
 
% CD3
+  
 54.3 [40.8-65.2] 53.6 [37.8-65.5] 56.3 [41.8-65.2] 0.560 
a
 
     
% CD4
+ 
 35.5 [25.6-49.1] 35.0 [21.1-46.7] 35.6 [26.6-51.8] 0.389 
a
 
                                 
% CD8
+  
 15.7 [10.1-22.4] 15.4 [9.7-22.6] 16.4 [10.5-22.8] 0.717 
a
 
     
% naïve, CD4
+
CD45RA
+
CD27
+ 
 
               
34.0 [22.5-48.5] 29.6 [17.9-48.3] 38.0 [27.0-49.8] 0.066 
a
 
    
% naïve, CD8
+
CD45RA
+
CD27
+
 20.5 [10.9-29.5] 16.7 [9.3-25.2] 24.6 [14.7-33.5] 0.003 
a
 
                   
% RTE, CD4
+
CD45RA
+
CD31
+ 
 
 
21.3 [14.2-33.4] 
 
20.3 [10.4-32.0] 
 
23.3 [16.8-33.5] 
 
0.176 
a
 
 
% RTE, CD8
+
CD45RA
+
CD31
+ 
 
 
37.6 [29.1-48.9] 
 
34.2 [24.7-46.4] 
 
44.9 [36.0-50.7] 
 
0.004 
a
 
 
TREC copy number/10
5
 PBMC 
 
19.0 [10.1-37.0] 
 
16.0 [7.7-31.5] 
 
25.0  [14.0-56.0] 
 
0.031 
a
 
 
Telomere length (T/S ratio)
c
 
 
1.15 ± 0.30 1.09 ± 0.31 1.22 ± 0.30 0.046 
b
 
Telomerase activity 
              n positive/n tested 
              Relative Units 
 
58/90 
5.6 [0.0-26.0] 
 
38/52 
14.6 [0.0-36.8] 
 
20/38 
1.4 [0.0-6.4] 
 
 
0.003
 a
 
a 
Mann-Whitney U test 
b 
Student t-test 
c 
Data are expressed as mean ± SD 
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FIGURE LEGEND 
 
Figure 1. Correlation between age and (A) TREC levels and (B) telomere lengths in 
cancer patients and controls. Panel (A): TREC levels decline with age in the peripheral 
blood cells of cancer patients (r=-0.478, p<0.001), but not in controls (r=0.071, p=0.677). 
Panel (B): telomere lengths decrease with age in peripheral blood cells of controls (r=-
0.354, p=0.031), but not in cancer patients (r=-0.011, p=0.938). 
 
Figure 2. CD8
+
 cell subsets distribution at baseline (A) and at follow-up (B). Pie 
charts show that frequencies of naïve and central memory cells did not significantly differ 
between baseline and follow-up (p=0.309 and p=0.137, respectively); conversely, the 
proportion of effector memory cells significantly declined (p=0.017), while terminally 
differentiated cells increased (p=0.031). 
 
Figure 3. Flow cytometry analysis of y-H2AX induction in controls and cancer 
patients. y-H2AX expression in untreated PBMC and after exposure to a dose radiation 
of 2.5 Gy at 24 h, in control (n=2) and cancer patients (n=3). Error bars represent standard 
deviation of the median fluorescence levels.  
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Figure 1. 
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Figure 2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
Figure 3. 
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Table 1S. Standard blood parameters: comparison between cancer patients and controls 
 
Parameter All patients 
Median [IQR] 
Cancer patients 
Median [IQR] 
Controls 
Median [IQR] 
p-value a 
Leucocytes (x109/l) 
 
Lymphocytes (x109/l) 
 
Neutrophils (x109/l) 
 
Hemoglobin (g/l) 
 
Platelets (x109/l) 
 
Total plasmatic proteins (g/l) 
 
Albumin (%) 
 
Gamma globulins (%) 
 
Triglycerides (mmol/l) 
 
Total cholesterol (mmol/l) 
 
LDL-cholesterol (mmol/l) 
 
HDL-cholesterol (mmol/l) 
 
Creatinine (umol/l) 
 
IgG (g/l) 
 
IgA (g/l) 
 
IgM (g/l) 
 
IL-6 (ng/l) 
 
CRP (mmol/l) 
 
CMV b 
    n positive/n tested (%)    
    IgG  (UI/ml) 
6.6  [5.3-7.9] 
 
1.6 [1.3-1.9] 
 
3.8 [3.0-4.9] 
 
127.0 [114.0-140.0] 
 
236.0 [204.0-291.0] 
 
66.8 [63.5-71.1] 
 
57.0 [54.0-59.6] 
 
15.2 [13.2-17.3] 
 
1.1 [0.8-1.4] 
 
4.9 [3.9-5.8] 
 
2.8 [2.0-3.7] 
 
1.4 [1.1-1.9] 
 
76.0 [68.0-93.0] 
 
10.5 [8.5-12.2] 
 
2.3 [1.8-2.9] 
 
0.9 [0.5-1.3] 
 
3.0 [1.9-5.3] 
 
3.5 [2.9-6.6] 
 
 
88/91 (96.7%) 
15000 [8200-21000] 
6.7 [5.5-7.9] 
 
1.7 [1.3-1.9] 
 
3.9 [3.2-4.9] 
 
128.0 [111.0-142.0] 
 
253.5 [212.5-317.0] 
 
68.4 [66.1-74.3] 
 
57.9 [54.7-60.6] 
 
14.9 [13.3-17.1] 
 
1.2 [0.8-1.7] 
 
5.1 [4.3-5.7] 
 
3.3 [2.7-3.8] 
 
1.4 [1.1-1.7] 
 
77.5 [68.2-95.0] 
 
10.3 [8.9-11.6] 
 
2.6 [1.8-3.4] 
 
0.8 [0.5-1.3] 
 
2.6 [1.9-4.3] 
 
3.5 [2.9-5.5] 
 
 
49/52 (94.2%) 
15000 [8125-19750] 
 
5.9 [5.0-7.5] 
 
1.5 [1.2-1.9] 
 
3.6 [2.7-4.9] 
 
126.0 [116.0-138.0] 
 
225.0 [183.0-260.0] 
 
64.0 [60.7-68.7] 
 
55.9 [53.9-58.2] 
 
15.8 [13.0-18.0] 
 
0.9 [0.7-1.2] 
 
4.5 [3.7-5.8] 
 
2.4 [1.7-3.6] 
 
1.6 [1.1-1.9] 
 
75.0 [68.0-93.0] 
 
11.0 [7.7-12.6] 
 
2.2 [1.6-2.7] 
 
0. 9 [0.5-1.4] 
 
3.7 [2.1-6.3] 
 
3.5 [3.4-10.8] 
 
 
100/100 (100%) 
15000 [9300-24000] 
0.110 
 
0.165 
 
0.141 
 
0.665 
 
0.011 
 
<0.001 
 
0.530 
 
0.549 
 
0.009 
 
0.229 
 
0.006 
 
0.194 
 
0.642 
 
0.934 
 
0.104 
 
0.853 
 
0.033 
 
0.044 
 
 
 
0.498 
                     a Mann-Whitney U test; b CMV serology: Serum CMV antibody (IgG) determined by ELISA; antibodies titers>230 were considered to be positive. 
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Table 2S. Relationship between markers of immune senescence and geriatric scores in cancer patients and controls 
 
 
 
TREC level  Telomere length  Telomerase activity 
 
All patients 
Cancer 
patients 
Controls 
 
All patients 
Cancer 
patients 
Controls 
 
All patients 
Cancer 
patients 
Controls 
MPI -0.03, 0.77 -0.04, 0.78 -0.24, 0.16  -0.04, 0.74 0.01, 0.95 -0.26, 0.13  -0.03, 0.81 0.16, 0.25 0.00, 0.98 
MMSE -0.1, 0.35 -0.28, 0.05
* -0.14, 0.42  0.06, 0.61 0.15, 0.28 -0.31, 0.06  -0.14, 0.19 -0.17, 0.22 0.19, 0.25 
CIRS-CI -0.04, 0.71 0.04, 0.79 -0.31, 0.07  0.04, 0.70 0.05, 0.72 -0.05, 0.76  -0.12, 0.26 0.01, 0.94 -0.18, 0.27 
CIRS-SI 0.26, 0.02
* -0.07, 0.61 0.45, 0.01**  0.16, 0.13 -0.11, 0.42 0.35, 0.03*  -0.06, 0.60 0.01, 0.95 0.18, 0.27 
GDS -0.03, 0.79 -0.19, 0.19 0.22, 0.18  -0.10, 0.34 -0.09, 0.54 -0.05, 0.75  -0.24, 0.02
* -0.20, 0.15 -0.26, 0.12 
BMI -0.03, 0.79 0.01, 0.96 -0.10, 0.57  0.02, 0.83 0.14, 0.31 -0.11, 0.53  0.27, 0.01
** 0.29, 0.04* 0.14, 0.39 
Concomitant 
drugs 
-0.01, 0.91 0.11, 0.43 -0.39, 0.02*  -0.13, 0.24 -0.18, 0.21 -0.24,0.15  -0.02, 0.89 0.13, 0.36 0.08, 0.65 
   Data are expressed as Spearman's rho coefficient, p-value. 
      *   
Correlation is significant at the level 0.05 (two-tailed) 
      ** 
Correlation is significant at the level 0.01 (two-tailed)
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Table S3. Flow cytometry markers of replicative senescence in cancer patients and 
controls 
  
 
 
Parameter
a
 
 
All patients 
Median [IQR] 
Cancer patients 
Median [IQR] 
Controls 
Median [IQR] 
 
p-value
b
 
 
                   
% CD4
+
CD28
-
CD57
+
 
 
6.6 [2.6-23.9] 
 
8.1 [1.9-33.3] 
 
5.8 [3.1-18.5] 
 
0.700 
 
% CD8
+
CD28
-
CD57
+
 
 
55.7 [49.9-62.4] 
 
58.5 [55.4-73.7] 
 
50.7 [38.5-58.9] 
 
0.092  
 
 
 a 
Flow cytometry was performed on frozen samples.
 
Cells were stained with the following labeled 
mAbs: anti-  CD3 (FITC), anti-CD4 (PerCP), anti-CD8 (PerCP), anti-CD57 (PE) and anti-CD28 
(APC). Appropriate isotypic controls (mouse IgG1-PE and mouse IgG2b-APC) were used to assess 
non-specific staining. All samples were analysed by four-color flow cytometry on a fluorescence-
activated cell sorter (FACS)Calibur (Becton-Dickinson). Data were processed with CellQuest Pro 
Software (Becton-Dickinson) and analysed using Kaluza
®
 Analysis Software v.1.2 (Beckman 
Coulter). The percentage of CD28
-
CD27
+
 was calculated within the CD3
+
CD4
+
 or CD3
+
CD8
+
 gate. 
CD28
-
CD27
+
 cells were defined as replicative senescent cells. 
 b 
Mann-Whitney U test 
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ABSTRACT 
 
Background. Several data indicate that HIV-infected adults undergo premature aging and 
immune senescence; chronic immune activation may play a critical role in these dysfunctions 
which, besides immune depression, may constitute important risk factors for the onset of 
AIDS-associated and non-AIDS associated malignancies in HIV-infected individuals. 
Limited data are available for HIV-infected children, in whom immune activation and 
senescence are likely to be more deleterious, since their immune system co-evolves from 
birth with HIV. 
 
Patients and Methods. 71 HIV-infected (HIV+) children, aged from 0-5 years, 65 HIV-
exposed-uninfected (HEU) and 56 HIV-1-unexposed-uninfected (HUU) age-matched 
children were studied. 42% of the HIV+ children were not on antiretroviral therapy (ART). 
Telomere length (TL) and T-cell receptor rearrangement excision circle (TREC) levels were 
quantified in peripheral blood cells by real-time PCR. Subgroups of 24 HIV+, 21 HEU and 
18 HUU children were studied for CD4
+
 and CD8
+
 cell differentiation (CD45RA, CD27, 
CD31), senescence (CD28, CD57) and activation/exhaustion (CD38, HLA-DR, PD-1) 
markers by flow cytometry. Statistical analyses were performed with  SPSS v22. 
 
Results. TL were significantly shorter in HIV+ than in HEU and HUU children (overall 
p<0.001, adjusted for age); moreover, HIV+ ART-naïve children had shorter TL compared 
with children on ART (median 2.11 [interquartile range (IQR) 1.75-2.37] vs 2.46 [2.07-2.68]; 
p=0.0029 adjusted for age). CD8
+
 recent thymic emigrant cells (CD45RA
+
CD31
+
) and TREC 
levels were significantly lower in HIV+ than in HEU and HUU groups (overall, p=0.005 and 
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p=0.0249, respectively), while percentages of CD8 effector memory (CD45RA
-
CD27
-
) and 
terminally differentiated cells (CD45RA
+
CD27
-
) were higher in the former (overall, p=0.033, 
and p<0.001, respectively). CD8 senescent cells (CD28
-
CD57
+
) were higher in HIV+ than in 
HEU and HUU children (25.8% [12.4-43.2] vs 8.5% [6.8-16.7] vs 9.7% [3.3-27.3]; p=0.004), 
as were CD8
+
 activated cells (CD38
+
HLA-DR
+
) (7.0% [5.2-12.2] vs 3.5% [3.9-7.6] vs 3.7% 
[2.4-6.7]; p<0.001) and CD8
+
PD-1
+
 cells (7.1% [5.0-12.4] vs 3.5% [2.1-5.9] vs 3.7% [2.4-
5.3]; p<0.001). Within CD4
+
 cell subset, percentages of senescent cells did not differ 
between HIV+ and controls, although PD-1
+
 expression tended to be up-regulated in HIV+ 
children (overall, p=0.050). 
 
Conclusions. HIV-infected children exhibit a premature biological aging with accelerated 
immune senescence which affects in particular the CD8
+
 cell subset. HIV infection per se 
seems to influence the aging process, rather than exposure to ART for prophylaxis or 
treatment. 
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1. INTRODUCTION 
The introduction of Antiretroviral Therapy (ART) has changed the natural history of 
pediatric HIV infection; indeed, ART-based prophylaxis regimens have reduced mother-to-
child transmission (MTCT) of HIV from 15-20% to under 2% in high-income countries and 
have also given rise to substantial improvements in terms of survival and quality of life in 
HIV-infected children [Gibb DM et al, BMJ 2003; Judd A et al, Clin Infect Dis 2007]. In 
view of this increased survival, HIV infection is now considered a chronic disease that 
persists for many decades [Deeks SG et al, Lancet 2013]. However, despite its improvement 
of the immune function and reduction of AIDS-related complications, including AIDS-
associated malignancies (ADM), ART does not restore full health. Indeed, many studies have 
evidenced that ART-treated HIV-infected adults have a higher risk of non-AIDS-related 
overall morbidity and mortality, compared to age-matched HIV-uninfected individuals. This 
increased risk is mainly due to a range of non-AIDS-defining illnesses that are associated 
with aging, including malignancies [Guaraldi G et al, Clin Infect Dis 2011], and it has been 
advanced that the increase of non-AIDS-defining diseases, including non-AIDS-defining 
malignancies (non-ADM) among HIV-infected patients is due to a premature aging [Effros 
RB, Clin Infect Dis 2008]. The pathogenic mechanism underlying this increased risk is still 
poorly understood. Chronic immune activation due to the persistence of circulating HIV 
virions may play a key role for the senescent pathway. Activated cells undergo clonal 
expansion in response to viral persistence, resulting in differentiation and accumulation of 
nonfunctional senescent cells [Desai S & Landay A, Curr HIV/AIDS Rep 2010]. It has been 
also advanced that premature and accelerated aging in HIV patients can be caused by adverse 
effects of antiretroviral drugs. Nucleoside reverse transcriptase inhibitors (NRTIs) have been 
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shown to inhibit telomerase activity in replicating cell lines in vitro, leading to accelerated 
shortening of telomere length, a marker of biological aging [Liu X et al, Nucleic Acids Res 
2007; Hukezalie KR et al, PloS One 2012].  
Clinical complications of HIV infection and ART treatment in children are more serious than 
in adults. The course of HIV infection in the former is characterized by faster disease 
progression and shorter time to AIDS, compared to adults. After infection, HIV plasma RNA 
levels are higher in vertically infected children than in adults. In addition they persist at high 
levels and decline slowly with age [De Rossi A et al, J Clin Invest 1996; McIntosh K et al, 
Pediatr Infect Dis J 1996], whereas in adults a control of viral load is reached within few 
weeks after infection [Henrard DR et al, JAMA 1995]. This gradual control of viral 
replication has been associated with increasing maturation and development of the immune 
system. The innate immunity, in children, is of particular relevance and plays a critical role in 
HIV pathogenesis [Ricci E et al, J Acquir Immune Defic Syndr 2009; Freguja R et al, New 
Microbiol 2012; Gianesin K et al, Plos One 2012] given that the adaptive immune system is 
still under development [Prendergast AJ et al, Nat Rev Immunol 2012]. Since in children the 
immune system co-evolves from birth with HIV and ART is required for decades, the effects 
of chronic immune activation and immune senescence together with ART toxicity in the 
course of their immune system’s maturation might be more deleterious.  
To date only little data are available on premature aging in HIV-infected children [Mansoor 
N et al, Clin Immunol 2009; Côté HC et al, PLoS One 2012; Diaz L et al, J Acquir Immune 
Defic Syndr 2012; Méndez-Lagares G et al, Clin Microbiol Infect 2013]. In this study we 
evaluated the status of biological aging and the degree of immune senescence in vertically 
HIV-infected children.  
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2. PATIENTS & METHODS 
2.1 Study Population 
A total of 71 perinatally HIV-infected (HIV+) children, aged 0-5 years, 65 exposed-
uninfected (HEU) and 56 unexposed-uninfected (HUU) age-matched children were included 
in the study. All HIV+ and HEU children attended to the Department of Mother and Child 
Health, University of Padova (Padova, Italy) or to the
 
Infectious Diseases Unit, Pediatrics 
Department, Hospital Saint Joan de Déu, Universitat de Barcelona, (Barcelona, Spain). For 
each HIV+ and HEU child, the first cryopreserved available sample after birth has been 
chosen for the study. No HIV+ or HEU child was breastfed. HUU children were recruited at 
the Pediatric Emergency Department of Azienda Ospedaliera Padova or Hospital Saint Joan 
de Déu, Universitat de Barcelona. Exclusion criteria were: malignancies, chronic infections, 
sarcoidosis, diabetes mellitus type-1, rheumatoid arthritis and systemic lupus erythematosus. 
The study was approved by the Ethics Committee of Azienda Ospedaliera Padova (Prot. 
n.#2921P); informed consent was obtained for patients and controls from their 
parents/guardians.  
 
2.2 Sample preparation  
Peripheral blood mononuclear cells (PBMC) were isolated from EDTA-treated peripheral 
blood by centrifugation on a Ficoll-Paque gradient (Pharmacia Biotech, Uppsala, Sweden). 
PBMC and plasma samples were cryopreserved and stored in liquid nitrogen until use. Two 
million PBMC were lysed as previously described [Righetti E et al, AIDS 2002]. 
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2.3 Telomere length measurement by quantitative real-time PCR  
Relative telomere length (TL) was determined by monochrome quantitative multiplex PCR 
assay [Cawthon RM, Nucleic Acids Res 2009] with minor modifications. Each PCR reaction 
was performed in a final volume of 25 µl containing 5 µl sample (~2 ng DNA/µl) and 20 µl 
reaction mix containing 0.75 x SYBR Green I (Invitrogen), 10 mM Tris-HCl pH 8.3, 50 mM 
KCl, 3 mM MgCl2, 0.2 mM each dNTP (Applied Biosystems), 1 mM DTT, 0.625 U 
AmpliTaq Gold DNA polymerase, 1% DMSO (Sigma) and 900 nM of each of the primers. 
The primer pair employed for telomere amplification were TELG 5’-
ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT-3’, and TELC 5’-
TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA-3’, and the primer pair 
for the amplification of the single-copy gene albumin were ALBU 5’-
CGGCGGCGGGCGGCGCGGGCTGGGCGGAAATGCTGCACAGAATCCTTG-3’ and 
ALBD 5’-GCCCGGCCCGCCGCGCCCGTCCCGCCGGAAAAGCATGGTCGCCTGTT-
3’. The single-copy gene albumin was amplified simultaneously with the telomere template 
in the same well and was used as a reference to adjust for different amounts of DNA in 
different samples. The PCR reactions were performed on a LightCycler
®
480 real-time PCR 
detection system (Roche Applied Science). The thermal cycling profile was 15 min at 95ºC, 
2 cycles of 15 s at 94ºC, 15 s at 49ºC, followed by 40 cycles of 15 s at 94ºC, 10 s at 62ºC, 15 
s at 74ºC, 10 s at 84ºC, 15 s at 88ºC, with signal acquisition at the end of both the 74°C and 
88°C steps. A standard curve was generated at each PCR run, consisting of DNA from the 
RAJI cell line serially diluted from 100 to 0.41 ng/µl. All DNA samples and reference 
samples were run in triplicate. LightCycler raw text files were converted to grid format using 
LC480Conversion free software developed by the Heart Failure Research Center (HFRC), 
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Amsterdam,Netherlands(http://www.hartfaalcentrum.nl/index.php?main=files&fileName=L
C480Conversion.zip&description=LC480%20Conversion&sub=LC480Conversion). The 
converted data were analyzed using LinRegPCR free software developed by Ruitjer et al 
[Ruitjer JM et al, Nucleic Acids Res 2009]. Mean Ct values were used to calculate the 
relative telomere length (TL) using the telomere/single-copy gene ratio according to the 
formula: ΔCtsample= Cttelomere - Ctalbumin, ΔΔCt = ΔCtsample - ΔCtreference curve (where ΔCtreference 
curve = Cttelomere_RAJI - Ctcontrol RAJI) and then T/S = 2
-ΔΔCt
 [Cawthon RM, Nucleic Acids Res 
2009]. Intra and inter-assay reproducibility of both telomere and albumin PCR results was 
evaluated using dilutions of the reference curve. The standard deviation of Ct values was 
≤0.19 (% coefficient of variation ≤0.94) in six replicates of samples amplified in the same 
PCR run, and ≤0.28 (% coefficient of variation ≤1.31) among mean values of triplicates in 
different PCR runs. 
 
2.4 T-cell receptor rearrangement excision circle (TREC) levels quantification 
Thymic output in PBMC was studied by measuring TREC levels by real-time PCR, as 
described previously [Ometto L et al, AIDS 2002]. TREC levels were expressed as the 
number of TREC copies per 10
5
 PBMC. 
 
2.5 Viral load quantification 
Plasma HIV RNA levels were determined in all HIV-infected children using the COBAS 
Taqman HIV-1 test (Roche, Branchburg, NJ, USA). The lower limit of detection was 50 HIV 
RNA copies/ml. HIV DNA levels in PBMC were measured by real-time PCR, as described 
previously [Ometto L et al, AIDS 2002]. The HIV copy number was normalized against the 
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TERT copy number, and the final results were expressed as HIV DNA copies/10
6
 cells. 
Samples for HIV DNA quantification were available for 44 children. 
 
2.6 Flow cytometry analysis 
T-cell phenotyping was performed on cryopreserved PBMC. Cells were thawed, washed, 
stained for 20 min in the dark with Live/Dead Fixable Near-IR Dead Cell Stain Kit (Life 
Technologies), and with fluorescent-conjugated mononuclear antibodies: CD3-FITC, CD31-
PE, CD38-PE, CD57-PE, CD45RA-APC and PD-1-PECy7 (Becton-Dickinson), CD27-
PECy7 (Beckman Coulter) and CD4-VioBlue, CD8-VioGreen, HLA-DR-APC and CD28-
APC (Miltenyi Biotec). Appropriate isotypic controls (mouse IgG1-PE, mouse IgG2b-APC 
and mouse IgG1k-PECy7) were used to evaluate non-specific staining. Cells were then 
washed with Automacs Buffer (Miltenyi BioteC) and resuspended in PBS supplemented with 
1% paraformaldehyde. All samples were analysed using LSRII Flow cytometer (Becton-
Dickinson Biosciences). A total of 100000 events were collected in the lymphocyte gate 
using morphological parameters (forward- and side-scatter). Data were processed using 
FACSDiva™ Software (Becton-Dickinson) and analysed using Kaluza® Analyzing 
Software v1.2 (Beckman Coulter). Figure 1 showed the gating strategies in identifying the 
CD4
+
 and CD8
+
 T-cell subsets. Samples for flow-cytometry analysis were available for 24 
HIV+ (15 with undetectable plasmaviremia (<50 copies/ml) and 9 with detectable 
plasmaviremia (median 3.64 [2.75-5.16] log10 copies/ml)), 21 HEU and 18 HUU children. 
Two HIV+ children were in therapy interruption at sample collection. 
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2.7 Statistical analysis 
Comparisons between groups were made using nonparametric tests, the Mann-Whitney U-
test or Kruskal-Wallis test, where appropriate. Correlations were explored using Spearman’s 
rho test. Linear regression was used to model the relationship between TL and age. Samples 
with undetectable plasma HIV RNA were assigned a value of 20 copies/ml to include them 
in the statistical analyses. All statistical analyses were performed using SPSS software 
version 22 (SPSS, Inc., Chicago, IL, USA). All P-values were two-tailed, and were 
considered significant when lower than 0·05. 
 
3. RESULTS 
3.1 Characteristics of the study population  
Characteristics of the 71 HIV+, 65 HEU and 56 HUU children are reported in Table 1. The 
median age of HIV+ children was 3.11 [interquartile range (IQR) 1.41-4.48 years], 1.73 
[0.99-3.20] years for HEU and 1.85 [0.85-3.46] years for HUU children. 30/71 (42%) HIV+ 
children were ART-naïve, while the remaining were in ART (median time of 18 [11.0-36.5] 
months). ART-naïve HIV+ children were younger than those under therapy (1.70 [0.69-3.59] 
and 3.62 [2.17-4.81] years, respectively; p=0.005). 61/65 (93.8%) HEU children were 
exposed to prophylaxis during gestational period (median 34 [17-38] weeks) and received 
postnatal prophylaxis (6 weeks of zidovudine (AZT) monotherapy). Regarding HUU 
children, 38 of them were hospitalized for acute infections (pneumonia, influence, 
gastroenteritis) and 18 were healthy and referred for minor surgery.   
 
 
83 
 
3.2 Telomere length is shorter in HIV-infected children 
The median TL in PBMC was significantly lower in HIV+ children than in HEU and HUU 
children, being the median TL of 2.21 [1.94-2.58], 2.63 [2.25-3.21], 2.88 [2.49-3.1], 
respectively (overall, p<0.0001 adjusted for age). TL inversely correlated with age in HEU 
and HUU groups (regression coefficient (β)=-0.01024, p=0.0079 and β=-0.01001, p=0.0112, 
respectively), but not in HIV+ children (β=-0.00175, p=0.5870) (Figure 2A). Of note, among 
HIV+ group, ART-naïve children had shorter TL compared with children on ART (2.11 
[1.75-2.37] versus 2.46 [2.07-2.68]; p=0.0029 adjusted for age). Neither for ART-naïve 
children nor for those on ART, TL was associated with age (β=-0.00540, p=0.2269; β=-
0.00455, p=0.2579, respectively) (Figure 2B).  
 
3.3 Thymic output is lower in HIV-infected children  
Given that an effective immune response depends on thymic function, thymic output was 
quantified by measuring TREC levels. HEU and HUU children had higher levels of TREC 
than HIV+ children (5409 [3411-6712], 5370 [2380-8101], 3498 [2051-6780] TREC 
copies/10
5
 PBMC; overall p=0.0249 adjusted for age). TREC levels decreased significantly 
with increasing age in HEU and HUU groups (β=-61, p=0.0088 and β=-86, p=0.0003, 
respectively), but not in HIV+ children (β=-17, p=0.3526) (Figure 2C). No significant 
differences in TREC levels/10
5
 PBMC were found between ART-treated children and ART-
naive children (p=0.2995) (Figure 2D).  
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3.4 Phenotypic T-cell alterations occur early in HIV-infected children 
There were no differences in the frequencies of CD3
+
 T cells between the three groups 
(overall, p=0.590). Percentage of total CD4
+
 T cells were lower in the HIV+ group than in 
the other groups (overall, p=0.001). Within CD4
+
 T cells, HIV+ children and control groups 
did not significantly differ in percentages of naïve (CD45RA
+
CD27
+
), central memory 
(CD45RA
-
CD27
+
), effector memory (CD45RA
-
CD27
-
) and terminally differentiated 
(CD45RA
+
CD27-) cell subsets (Table 2). However, when central and effector memory cell 
subsets, the major cellular reservoirs for HIV [Chomont N et al, Nat Med 2009] where 
considered together,  they tended to be lower in HIV+ children than in HEU and HUU 
children [21.9% [15.3-38.3] versus 29.8% [18.6-39.4] and 34.3% [24.1-42.6]; p=0.158). 
Percentage of senescent cells (CD4
+
CD28
-
CD57
+
) were similar between the three groups 
(p=0.568), while activated CD38
+
HLA-DR
+
 and exhausted PD-1
+
 were more expanded in 
HIV+ children than in controls. In particular, CD4
+
CD38
+
HLA-DR
+
 and CD4
+
PD-1
+
 were 
higher in children with detectable viral load than in aviremic children (p=0.056 and p=0.037, 
respectively). 
The median of CD8
+
 cell percentage tended to be higher in HIV+ children than in control 
groups (overall, p=0.063). Notably, significant differences emerged among CD8
+
 cell 
subsets. HIV+ children showed a lower percentage of naïve cells (CD45RA
+
CD27
+
) than 
HEU and HUU children (46.2% [37.6-75.1], 77.1% [55.9-84.7], 71.0% [46.7-86.1]; overall 
p=0.019). In particular, HIV+ children had a lower frequency of CD8
+
 recent thymic 
emigrant (RTE) (overall, p=0.005) and a higher percentage of peripheral expanded cells 
(PEC; CD45RA
+
CD31
-
) than control groups (overall, p=0.040), suggesting a strong 
peripheral proliferation. Moreover, the amount of CD8
+
 RTE cells decreases with age in 
85 
 
HEU and in HUU children, but not in HIV+ children (Figure 3A-C). Interestingly, CD8
+
 
RTE cells were lower in children with detectable viral load than in aviremic children (41.8% 
[22.6-64.4] versus 55.9% [53.6-76.7], p=0.039), and tended to inversely correlate with HIV 
RNA (r=-0.363, p=0.080) (Figure 3D). Taken together, these findings suggest that, likely 
because the pressure exerted by HIV, RTE cells are induced to rapidly proliferate in order to 
mount an effective response against viral antigens.  
The alteration of thymic function in HIV+ children is also evidenced by the absence of 
correlation between CD4
+
 RTE and CD8
+
 RTE, as shown in Figure 4A, conversely from 
what is observed in HEU and HUU children (Figure 4B and C). 
Among memory cell subsets, frequency of CD8
+
 central memory did not differ between 
HIV+, HEU and HUU children (overall p=0.278); however in the HIV+ group, this subset 
was more expanded in children with detectable viremia than in those with undetectable HIV 
RNA (p=0.027) (not shown). Both effector memory (CD45RA
-
CD27
-
) and terminally 
differentiated cells (CD45RA
+
CD27
-
) were more expanded in HIV+ children than in control 
groups (Table 2). Furthermore, in HIV+ children the proportion of CD8
+
 cells with a 
senescent phenotype (CD28
-
CD57
+
) was higher than in HEU and HUU groups (25.8% [12.4-
43.2] versus 8.5% [6.8-16.7] and 9.7% [3.3-27.3]; p=0.004). This expansion was observed 
only in children with detectable plasmaviremia, suggesting that the presence of viral load 
stimulates the production of a senescent phenotype (41.6% [18.5-45.8] versus 4.4% [2.1-
13.4]; p=0.002). Additionally, the activation of CD8
+
 (CD38
+
HLA-DR
+
) cells was 
significantly higher in HIV+ children than controls, being the median 6.9% [4.4-12.2] versus 
4.5% [3.7-7.6] in HEU and 3.5% [2.9-7.6] in HUU children (overall p=0.015), and increased 
significantly with HIV RNA levels (r=0.672; p<0.001). In all groups, the percentage of 
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activated CD8
+
 cells correlated with the percentage of senescent cells (HIV+: r=0.505, 
p=0.016; HEU: r=0.731, p<0.001; HUU: r=0.564, p=0.027). Surprisingly, the frequency of 
CD8
+
 activated cells tended to be higher in HEU children than in HUU (4.7% [3.9-7.6] 
versus 3.4% [2.8-6.7] cells/ul; p=0.083). The percentage of PD-1 expressing CD8
+
 cells were 
significantly higher in HIV+ children than in HEU and HUU groups (overall p=0.003 and 
p<0.001, respectively). In particular, PD-1 expression in viremic subjects was significantly 
higher than in those with undetectable plasmaviremia (p=0.002), and correlated with HIV 
RNA levels (r=0.471, p=0.021) and immune activated cells (CD8
+
CD38
+
HLA-DR
+
) markers 
(r=0.528, p=009). 
As shown in Figure 5, telomere length was inversely correlated with percentages of CD8
+
 
senescent (Figure 5A), activated (Figure 5D) and exhausted cells (Figure 5G) in HIV+ 
children, but not in HEU (Figure 5B, E, H) and HUU children (Figure 5C, F, I).  
 
4. DISCUSSION 
This is the first study describing biological aging and immune senescence in HIV-infected 
children (aged 0-5 years), compared with age-matched HIV-exposed-uninfected and 
unexposed-uninfected children.  
Overall, the results demonstrated that HIV-infected children exhibit a premature biological 
aging with an accelerated immune senescence that affects in particular the CD8
+
 T-cell 
subset. Conversely, from the CARMA cohort study of Côté et al. [Côté HC et al, PLoS One 
2012], in which no difference in telomere length was found between HIV+ children and 
HIV- controls, in our study telomere length was significantly shorter in HIV-infected 
children than in HEU and HUU children. This discordant result could be due to the different 
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age of the two cohorts: children enrolled in our study are younger (aged 0-5 years, median 
3.1) compared to those of Côté’s study (aged 0-19 years, median 13.3). As telomere 
shortening in PBMC is very rapid during the first 3 years of life [Zeichner SL et al, Blood 
1999], it is possible that in our cohort the difference between HIV+ and controls has better 
emerged. Moreover, the two cohorts differed for the duration of ART exposure. The longer 
exposure among children of CARMA cohort (median 338 weeks), resulting in a better 
control of plasmaviremia and in a reduction of immune activation, may lead to a loss of 
association that conversely was found in our study population, consisting of ART-naïve or 
recently under ART (median 48 weeks) children. Among HIV+ group, the shorter telomere 
length in PBMC of ART-naïve compared to ART-treated children suggests that HIV 
infection per se, rather than exposure to therapy, influences the aging process. The 
mechanism behind shorter telomere length in HIV-infected individuals is unknown. Short 
telomere lengths could be due to an excessive cellular replication consequent to chronic 
immune activation, but virus in itself may play an active role. Interestingly, our results could 
be partially explained by the evidence that telomerase activity is severely impaired in 
uninfected CD34
+
 haematopoietic progenitor cells isolated from HIV-infected patients 
[Vignoli M et al, AIDS 1998]. Moreover, HIV-infection and HIV-Tat protein have been 
shown to down-modulate telomerase expression and activity in lymphoblastoid cells and in 
peripheral blood lymphocytes [Ballon G et al, J Infect Dis 2001; Reynoso R et al, AIDS Res 
Hum Retroviruses 2006; Comandini A et al, Mol Immunol. 2013].  
Despite CD4
+
 T-cell subset is the target of HIV-infection, analysis of T-cell phenotype 
showed that also CD8
+
 T-cell compartment is largely impaired in the HIV-infected children. 
HIV+ children had a lower frequency of CD8
+
 naïve cells, whose reduction does not 
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correlate with age as it occurs in the control groups. In particular, the production of new 
CD8
+
 cells, identified by the expression of CD31 marker, decreases with parallel increasing 
level of HIV plasmaviremia, suggesting that HIV induces CD8
+
 peripheral expansion and 
differentiation into effector cells, which play a central role in immunity against viruses by 
producing cytokines and by killing infected target cells [Northfield JW et al, J Virol 2007]. 
As already described in cohorts of adults and older children [Brenchley JM et al, Blood 2003; 
Montesano C, New Microbiol 2010; Diaz L, J Acquir Immune Defic Syndr 2012], the 
decrease of naïve cell subset is associated with a skewed maturation of CD8
+
 T-cell towards 
an effector phenotype that, without an adequate replenishment of new CD8
+
 naïve cells, that 
induces an accumulation of cells with a senescent phenotype. The evidence that immune 
senescence is more serious in children with detectable HIV viremia focuses the need to 
control HIV replication and chronic immune activation. In particular, this aspect must be 
taken into consideration when a treatment interruption has been planned [Klein N et al, PLoS 
One 2013]. Notably, the importance to control the levels of immune activation is also shown 
by studies during infancy and in older HEU children that revealed immunological alterations 
from HUU [Clerici M et al, Blood 2000; Vigano A et al, AIDS 2007; Afran L et al, Clin Exp 
Immunol 2014]. 
In conclusion, HIV-infected children exhibit a premature biological aging with an accelerated 
immune senescence that affects in particular the CD8
+
 T-cell subset. The lower telomere 
length and the higher percentages of senescent cells in HIV+ children, compared to children 
on ART or HEU, suggest that HIV infection in itself, rather than exposure to ART for 
prophylaxis or treatment, influences the aging process. These data support the importance of 
maintaining undetectable viral load to avoid premature immune senescence and dysfunction 
89 
 
of CD8
+
 cells, compromising their tumor immune surveillance function and increasing the 
risk of malignancies. Although ART suppresses viral load and partially restores immune 
functions, immunological alterations persist in ART-treated children making them more 
vulnerable to cancer development compared to controls.  
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Table 1. Demographic and clinical characteristics of HIV+, HEU and HUU children 
 
 
HIV+ (n=71) HEU (n=65) HUU (n=56) 
Age, median [IQR] yrs 3.11 [1.40-4.48] 1.74 [0.99-3.31] 1.85 [0.84-3.46] 
Gender, n (%) 
   
                              M/F 39 (55%)/32 (45%) 
34 (52%)/31 
(48%) 29 (52%)/27 (48%) 
Exposed to prophylaxis, n (%) 5 (7%) 61 (93.8%) - 
Exposed to ART, n (%) 41 (58%) - - 
Duration of ART exposure,  
median [IQR] weeks 48 [72-144] - - 
Percentage of lifetime on ART 57.5 [42.6-84.5] - - 
Detectable plasmaviremia, n (%) 55 (77.5%) - - 
Plasmaviremia at sample collection 
 (log10 copies/ml) 
 
- - 
                                 ART-naive 5.25 [4.75-5.60] - - 
                                     on ART 1.70 [2.54-4.28] - - 
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Table 2. Frequencies of CD4
+
 and CD8
+
 subsets 
 
  
HIV+ (n=24) HEU (n=21) HUU (n=18) 
 overall 
p-value 
      CD3
+
 
       % 64.4 [58.8-69.2] 61.8 [49.8-68.4] 60.2 [54.6-66.4] 0.590 
CD4
+
 
       % 39.6 [35.1-45.3] 53.4 [43.5-64.7] 52.5 [38.0-60.6] 0.001 
naive 
       % 76.8 [59.9-84.4] 70.1 [59.9-81.0] 64.7 [56.9-75.3] 0.423 
central memory 
       % 18.1 [13.2-31.1] 27.3 [17.4-32.6] 27.9 [20.7-35.1] 0.206 
effector memory 
       % 3.4 [1.2-5.8] 2.5 [1.8-6.3] 4.4 [2.9-7.8] 0.220 
t. differentiated 
       % 0.5 [0.2-1.0] 0.3 [0.1-0.6] 0.4 [0.3-0.1] 0.330 
RTE 
       % 63.6 [54.9-72.4] 58.3 [46.0-68.2] 54.2 [49.3-61.7] 0.181 
PEC 
       % 12.4 [5.3-16.4] 11.7 [8.2-16.1] 10.4 [8.1-15.2] 0.738 
senescent 
       % 0.4 [0.1-0.7] 0.2 [0.1-0.5] 0.2 [0.1-1.3] 0.568 
activated 
       % 3.3 [2.2-5.9] 2.1 [1.3-3.5] 2.8 [1.6-3.8] 0.041 
exhausted 
       % 4.1 [3.4-6.6] 3.5 [1.9-5.2] 3.2 [2.7-5.1] 0.050 
CD8
+
 
       % 31.2 [25.8-39.6] 28.9 [21.2-35.0] 25.9 [22.8-29.0] 0.063 
naive 
       % 46.2 [37.6-75.1] 77.1 [55.9-84.7] 71.0 [46.7-86.1] 0.019 
central memory 
       % 11.0 [6.9-23.2] 16.3 [10.9-26.5] 12.7 [9.8-18.9] 0.278 
effector memory 
       % 7.1 [2.3-13.1] 2.1 [1.1-4.9] 4.3 [1.3-11.4] 0.033 
t. differentiated 
       % 16.3 [4.5-36.4] 2.5 [1.0-8.6] 4.2 [2.1-16.2] 0.001 
RTE 
       % 55.3 [41.4-71.8] 69.8 [60.4-80.1] 68.1 [59.5-79.3] 0.005 
PEC 
       % 17.1 [6.5-29.2] 5.9 [3.8-15.3] 9.8 [4.6-15.2] 0.040 
senescent 
       % 25.8 [12.4-43.2] 8.5 [6.8-16.7] 9.7 [3.3-27.3] 0.004 
activated 
       % 7.0 [5.2-12.2] 4.7 [3.9-7.6] 3.4 [2.8-6.7] <0.001 
exhausted 
       % 7.1 [5.0-12.4] 3.5 [2.1-5.9] 3.7 [2.4-5.3] <0.001 
Ratio CD4
+
/CD8
+
 
        1.23 [0.97-1.87] 1.78 [1.20-2.43] 1.81 [1.59-2.11] 0.026 
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FIGURE LEGENDS 
 
Figure 1. Example of flow cytometry gating strategy to identify CD4
+
 and CD8
+
 cell 
subsets. Lymphocyte population was identified using FSC versus SSC plot (A), to select live 
cells (B). Sequential gating was used to select the total CD3
+
 cell population (C) and the 
CD3
+
CD4
+
 and CD3
+
CD8
+
 cell subsets (D). Within CD3
+
CD4
+
 or CD3+CD8+ gate, 
CD45RA and CD27 markers were used to identify naïve (CD45RA
+
CD27
+
), central memory 
(CD45RA
-
CD27
+
), effector memory (CD45RA
-
CD27
-
) and terminally differentiated cells 
(CD45RA
+
CD27
-
) (E); CD45RA and CD31 markers were used to identify recent thymic 
emigrant (RTE, CD45RA
+
CD31
+
) and peripherally expanded cells (PEC, CD45RA
+
CD31
-
) 
(F); CD57 and CD28 markers were used to select senescent cells (CD28
-
CD57
+
) (G); CD38 
and HLA-DR were used to identify activated cells (CD38
+
HLA-DR
+
) (H); finally, exhausted 
cells were identify by the expression of PD-1 (I).  
 
Figure 2. Correlation between age and telomere length (A-B) and TREC levels (C-D). 
(A) Telomere length as function of age in HIV+ (in black), in HEU (in grey) and HUU (in 
white) children. (B) Telomere length as function of age in HIV+, subdivided in ART-naïve 
(in grey) and ART-treated children (in black). (C) TREC levels as function of age in HIV+ 
(in black), in HEU (in grey) and HUU (in white) children. (D) TREC levels as function of 
age in HIV+, subdivided in ART-naïve (in black) and in ART-treated children (in grey). 
 
Figure 3. Correlation between frequency of CD8
+
 recent thymic emigrants cells and age 
(A-C) and viral load (D). Scatter plots showing correlation between age and %CD8
+
 RTE 
cells in HUU (A), HEU (B) and HIV+ (C) children. (D) Relationship between HIV-1 viral 
load and %CD8
+
 RTE cells in HIV+ children.  
 
Figure 4. Correlation between CD4
+
 and CD8
+
 recent thymic emigrants cells. Scatter 
plots showing absence of correlation between frequencies of naïve CD4
+
 and CD8
+
 RTE 
cells in HIV+ children (A); conversely,  a strong relationship was found in HEU (B) and 
HUU (C) children. 
 
Figure 5. Correlation between telomere length and percentages of senescent (A-C), 
activated (D-F) and exhausted cells (G-I). Telomere length correlates with senescent cells 
in HIV+ (A) children but not in HEU (B) and HUU (C) children. In addition, in HIV+ 
children, telomere length was inversely correlated with activated (D) and exhausted (G) cells; 
conversely, these relationships were not found in HEU (E, H) and HUU (F, I) children.  
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4. GENERAL CONCLUSIONS 
This research PhD program has been conducted in the frame of exploratory studies, aimed at 
evaluating the immune senescence and biological aging in two populations at higher risk of 
cancer. 
1. The world's population is aging and, since cancer incidence increases exponentially with 
advancing age, diagnosis of new cancer cases among elderly people is expected to increase 
significantly in the coming years, leading to important issues for their treatment. Aging is a 
multidimensional process difficult to define well; elderly cancer patients differ each other in 
their biologic age, metabolism, comorbid conditions, life expectancy, performance status, 
social status, and in their treatment preferences (side-effects profile and convenience). In this 
light, the need to better define this more vulnerable population is growing. Our study 
represents the first attempt to investigate cellular parameters associated with immune aging 
and senescence in elderly cancer patients, alongside a thorough cognitive and frailty 
assessment. We found that in elderly cancer patients immune senescence is significantly 
worse compared to age-matched controls. Indeed, cancer patients have lower thymic output, 
lower percentages of naïve CD8
+
 and recent thymic emigrant CD8
+
 cells, but an expanded 
CD8
+
 memory pool. Moreover, they have lower telomere length in peripheral blood cells. 
The fact that control patients present a more severe burden of associated diseases enforces 
the magnitude of the difference observed for these immune senescence and biological aging 
markers between the two groups, and it makes the possibility of a pre-existing condition that 
would facilitate the onset of malignancies. In addition, preliminary data available from the 
follow-up substudy seem to indicate that adjuvant chemotherapy aggravates the aging 
process. These findings are in agreement with other studies [Unryn BM et al, Clin Cancer 
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Res 2006; Sanoff HK et al, J Natl Cancer Inst 2014] conducted in younger cohorts. These 
observations could have important implications for the clinical treatment in elderly cancer 
patients. Indeed, the chemotherapy-related DNA-damage may have a synergistic effect on 
relapse risk, since it occurs in a setting of age-related reduction of DNA-damage repair 
ability [Scarpaci S et al, Ageing Dev 2003]. Our study highlights the value of aging 
biomarkers in addressing adjuvant chemotherapy to those patients who may better benefit 
without late side-effects risk. However, the little number of subjects included in the study 
undoubtedly represents a limitation to the study. In order to consolidate these findings, the 
enrolment of other patients is in progress. 
2. With the advent of ART and the consequent substantial improvement in life expectancy, 
the proportion of perinatally HIV-infected children that become adolescents and young adults 
is expanding. The aim of our study was to assess parameters of biological aging and immune 
senescence in the context of HIV infection, given the increasing data about the excessive risk 
of age-related morbidity, particularly in malignancies. Our study demonstrated that HIV-
infected children had a lower telomere length compared to age- and gender- matched 
controls, suggesting an accelerated biological aging. The phenotypic analysis of peripheral 
blood cells revealed that immune senescence is worse in CD8
+
 cell compartment than in 
CD4
+
, and it is mainly due to the accelerated replication of CD8
+
 cells in their attempt to 
control the viral infection. Indeed, in HIV-infected children but not in control groups, 
telomere length was inversely correlated with frequency of senescent, activated and 
exhausted cells. Moreover, age-adjusted telomere length is shorter in ART-untreated than in 
ART-treated children, thus suggesting that HIV itself, rather than exposure to antiretroviral 
drugs, influences the aging process. It is known that NRTIs are able to inhibit telomerase 
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activity in vitro, leading to accelerated shortening of telomere length [Liu X et al, Nucleic 
Acids Res 2007; Hukezalie KR et al, PLoS One 2012], but no study has proved that NRTIs 
inhibited telomerase activity in vivo. The inverse association between telomere length and 
duration of NRTI-containing ART has been recently demonstrated in a cohort of adults 
[Leeansyah E et al, J Infect Dis 2013], but the small sample size and lack of an optimal 
control of ART-naïve patients preclude definitive conclusions. The shortening of telomeres is 
a slow process, and it is possible that, in this study, we were not able to find any association 
between telomere length and ART, because the exposure was not long enough (median time 
of ART exposure 48 [72-144] weeks).  
Overall, these findings, together with the evidence that a worse immune senescence may 
predispose to cancer onset, highlight the importance to control immune activation and the 
need to maintain a persistent viral suppression, in order to delay the aging process that seems 
already compromised at birth. In addition to current assays, i.e. HIV plasmaviremia and 
CD4
+
 cells profile, our study indicates the relevance to analyze telomere length and CD8
+
 
cell subsets to assess the status of premature aging and immune senescence in this population 
at high risk of cancer. 
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